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Spatially and temporally organized cell differentiation and tissue 
morphogenesis characterize the whole embryo development process, and 
unintended exposure to teratogenic compounds can lead to various birth 
defects. However, current animal-based models for developmental toxicity 
testing is limited by time, cost and high inter-species variability, while human 
pluripotent stem cell (hPSC) models are only focusing on recapitulating cell 
differentiation with neither spatial control nor morphogenic movements.  
In this dissertation, a human-relevant in vitro model, which recapitulated 
two cellular events characteristic of embryogenesis, was developed to identify 
potentially teratogenic compounds. Firstly mesoendoderm differentiation was 
only induced to the periphery of micropatterned hPSC (μP-hPSC) colonies, 
where there were higher integrin-mediated adhesions compared with colony 
interior. Spatially polarized integrin adhesions in a cohesive hPSC colony 
compete to recruit Rho-ROCK activated myosin II away from E-cadherin 
mediated cell-cell junctions to promote differentiation at that locality, resulting 
in a heterogeneous cell population. When further inducing the mesoendoderm 
differentiation from 1 day to 3 days, tissue morphogenesis could be 
recapitulated, which was mainly collective cell migration in vitro. Cells at the 
colony periphery actually underwent epithelial-mesenchymal transition (EMT) 
and directed collective cell migration to form an annular mesoendoderm 
pattern which was similar as in vivo. When treated with known teratogens, the 
 ii 
 
two cellular processes (cell differentiation and collective cell migration) were 
disrupted and the morphology of the mesoendoderm pattern was altered. 
Image processing and statistical algorithms were developed to quantify and 
classify the compounds’ teratogenic potential. The μP-hPSC model not only 
could capture the dose-dependent effects of teratogenicity but also could 
correctly classify species-specific drug (Thalidomide) and false negative drug 
(D-penicillamine) in the conventional mouse embryonic stem cell test. This 
model offers a scalable screening platform to mitigate the risks of teratogen 
exposures in human.  
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1. Introduction  
Developmental toxicology is the study of effects of toxic chemicals and 
physical agents on the developing offspring [1]. In presence of xenobiotics 
such as certain pharmaceutical drugs and pesticides, deviant embryo 
development may happen due to their developmental toxicity such as death, 
malformation, growth retardation, and functional deficiency. Up to now, many 
drug screening methods have been developed to evaluate the developmental 
toxicity of various xenobiotics, including both in vivo and in vitro platforms. 
Animal-based in vivo tests used to be the only generally accepted methods for 
developmental toxicity testing. However, they are also known to be the most 
animal-consuming and expensive tests across all the animal-based tests on any 
chemicals. For each individual test, 560 animals are needed on average for 
developmental toxicity screening and 3,200 animals are needed for two-
generation reproductive toxicity studies, which cost €54,600 and €328,000 
respectively [2]. In addition, these in vivo tests are based on the fundamental 
assumption that animal models can predict human response in developmental 
toxicity testing and risk assessment. However, studies have shown that there is 
no more than 60% correlation between different laboratory mammalian 
species in developmental toxicity responses [3, 4], indicating a high inter-
species variation. 
In order to reduce animal use in developmental toxicity testing, different 
in vitro methods have been developed for decades. These methods mainly 
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include the frog embryo teratogenesis assay (FETAX) on xenopus [5], the 
chicken embryo toxicity screening test (CHEST) [6], the micromass (MM) 
assay using mouse embryonic mesenchymal cells [7], the mammalian whole 
embryo culture (WEC) assay using mouse [8] or rat, the zebrafish embryo-
larva developmental toxicity assay [9], and the mouse embryonic stem cell test 
(mEST) [10]. However, to date, none of these methods has been fully proven 
to give reproducible results sufficiently similar to the results of in vivo tests 
and human data. In addition, another major limitation is that still animal cells 
or embryos are applied in these platforms, meaning that the inter-species 
variation problem cannot be avoided.  
Since the successful isolation and continuous in vitro culture of human 
embryonic stem cells (hPSCs) in 1998 [11], several groups have been trying to 
establish hPSC-based in vitro models to conquer the inter-species variation 
problem and produce more human-relevant data [12-17]. Although different 
downstream evaluation methods were applied, almost all of these models were 
developed in a temporally-controlled differentiation context using either 
directed differentiation (i.e., neural or cardiac differentiation etc.) or random 
differentiation [12, 14-17]. However, in human development, tissue 
morphogenesis, which involves cell migration, cell shape changes, selective 
cell growth and apoptosis [18, 19], is equally important and interrelated with 
regulated cell differentiation in correctly forming different developmental 
structural motifs at different phases of development [20, 21]. Therefore, a 
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hPSC-based model which can capture not only differentiation but also the 
morphogenesis aspect of development might produce more in vivo-related 
drug testing responses and higher predictivity in developmental toxicity 
screening.  
The primary objective of this dissertation is to establish such a hPSC-
based model encompassing both spatial patterned differentiation and 
morphogenetic movements, and apply it for developmental toxicity screening. 
A complete review of all the background information is presented in Chapter 2. 
Chapter 3 presents the three specific aims of this dissertation, mainly to study, 
characterize and apply this in vitro hPSC-based model for developmental 
toxicity screening. Chapter 4-6 mainly introduce the research designs and 
findings of each of the three aims. Chapter 7 concludes the dissertation and 




2. Background and Significance 
This chapter introduces the background information of the studies 
presented in this dissertation. In order to detect the developmental toxicity 
potential of compounds in vitro, a model which could recapitulate real embryo 
development events is most preferable. To achieve that, a basic understanding 
of human embryo development is necessary. Section 2.1 summarizes the 
characteristics of and the main factors regulating the embryo development, 
which provides the general guideline for developing in vitro development 
systems for either mechanism studies or compound screening. Section 2.2 
explains the features and significance of developmental toxicity testing, and 
gives a summary of current in vivo animal models. Section 2.3 and Section 2.4 
introduce main existing in vitro animal-based models and hPSC-based models 
for developmental toxicity screening respectively.  
2.1 Embryogenesis 
This section will first give a general idea of mammalian embryogenesis, 
and then will cover the two main factors regulating normal embryo 
development, which are biochemical signalling and mechanical transduction.  
2.1.1 Mammalian embryogenesis 
Basic events in embryogenesis are believed to be highly conserved across 
species, even for species as disparate as fruit flies, frogs, mice and humans. 
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Basketter says that “ this degree of conservation mainly applies to the most 
fundamental processes in embryogenesis, such as establishment of the general 
body plan, pattern formation, cellular induction, and regulation of 
differentiation via signalling pathways” [3]. In mammals, embryogenesis 
refers mainly to early stages of prenatal development, while fetal development 
describes later stages. The whole embryogenesis process mainly includes 
fertilization, cleavage and morula, formation of the blastula, gastrulation and 
organogenesis. Among all these stages, gastrulation is believed to be the most 
important step of development in forming the body plan. It’s the process of 
gastrula formation, during which the single-layered blastula is reorganized into 
a three-germ-layered structure including endoderm, mesoderm and ectoderm. 
The three germ layers will eventually give rise to all the tissues and organs of 
a mammal through organogenesis. The endoderm will form the digestive, 
respiratory and urinary organs, the ectoderm will give rise to epidermis and 
the nervous system, and the mesoderm will form all other tissues and organs 
such as connective tissue and the organs that belong to the motor and 




Figure 2.1.1 Gastrulation in a chick embryo. ( Adapted from [22] )  
Gastrulation starts when the primitive streak forms on the posterior side of 
the embryo. After that, epiblast cells which ingress through the primitive 
streak form definitive endoderm and mesoderm, whereas the anterior cells of 
the epiblast will differentiate into ectodermal lineages (Fig. 2.1.1) [23]. The 
correct gastrula formation, together with other stages of embryogenesis, needs 
not only the correct cell fate control, but also the correct self-organized spatial 
control within the embryo. In fact, another key event characterizing 
embryogenesis, other than cell differentiation, is tissue morphogenesis. Tissue 
morphogenesis involves cell migration, cell shape changes, selective cell 
growth and apoptosis [18, 19].  It interrelates with and is equally important as 
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regulated cell differentiation to correctly form different developmental 
structural motifs at different phases of development at their desired position 
[20, 21]. During gastrulation, main morphogenetic movements include 
invagination, ingression, involution, intercalation and directed migration, all of 
which are conserved across species (Fig. 2.1.2) [24]. Invagination, ingression 
and involution are three movements responsible for internalization. 
Invagination is a process of groove formation in a tissue sheet via cell shape 
changes such as apical constriction, which occurs during primitive streak 
formation. Ingression follows invagination, when cells in the groove will 
undergo epithelial mesenchymal transition (EMT) to become motile 
mesoendoderm cells and move freely beneath the surface layer. Involution is a 
movement of cell sheet rolling, normally over an edge or itself. Similar as 
ingression, cells at the leading edge can undergo EMT and move on the 
overlying tissue sheet. Intercalation entails radial cell intercalation and 
mediolateral cell intercalation, which results in either thinning and surface 
expansion of tissue (the former), or simultaneous convergence and extension 




Figure 2.1.2 Morphogenetic movements of cells during gastrualtion. (A) 
Gastrulation movements can be classified based on the morphogenetic 
changes they produce. Epiboly leads to expansion of tissue, often 
accompanied by thinning. Emboly or internalization entails movement of 
mesodermal and endodermal precursors from the blastula surface beneath the 
prospective ectodermal layer. Convergence narrows tissues mediolaterally, 
whereas extension elongates them from head to tail. (B–H) Each class of 
gastrulation movements can be achieved by a variety of morphogenic cell 
movements. (Adapted from [24]) 
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2.1.2 Biochemical control during gastrulation 
Due to the fact that basic events in embryogenesis are believed to be 
highly conserved across species, many studies have been done using different 
species to understand mammalian embryogenesis. Biochemical signalling has 
been shown to be essential in cell fate determination for decades. 
Activin/Nodal, Wnt, and BMP signalling pathways are reported to be 
important for the mesoendoderm differentiation in gastrulation stage [25, 26]. 
Nostro et. al. (2007) found that Activin/Nodal and Wnt signalling are essential 
for the induction of primitive streak, the formation of which marks the start of 
gastrulation [25]. BMP signalling, however, although not required for 
primitive streak induction, has a strong posteriorizing effect on this population 
to correctly induce F1k
+
 mesoderm.  
 Nodal signalling actually influences the embryogenesis since blastula 
stage [27]. There are three lineages in a mammalian blastula. The epiblast give 
rise to the embryo and later the fetus itself, the trophoblast develops into part 
of the placenta, and the primitive endoderm becomes the yolk sac. Nodal is 
activated through the developing epiblast by convertase enzymes secreted 
from the extraembryonic ectoderm and helps establishing the proximal-distal 
(PD) axis during blastula stage, which rotates and becomes the anterior-
posterior (AD) axis [28, 29]. After Nodal is activated, it can autoregulate itself 
and activate BMP in the extraembryonic ectoderm. The activated BMP will 
then induce Wnt in the adjacent epiblast [30]. Wnt signals can concentrate 
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Nodal to the proximal epiblast by activating the proximal epiblast enhancer 
(PEE) in the Nodal gene [31]. A Nodal PD gradient will eventually form 
through the induction of the endogenous inhibitors Lefty1 and Cerberus in the 
distal visceral endoderm (DVE) by activated Nodal in the proximal epiblast.  
Nodal expression will be restricted to the proximal side of the embryo, where 
the primitive streak will locate. The PD axis will rotate to be the AP axis. 
Nodal is then expressed in the primitive endoderm and co-ordinates its 
directional migration and elongation [32]. When gastrulation is complete, 
Nodal expression will be restricted to the periphery of the node at the anterior 
end of the primitive streak [33].  
On the other hand, Wnt signals can be transduced either to the canonical 
pathway for cell fate determination, or to the noncanonical pathway for control 
of cell movement and tissue polarity [34]. Canonical Wnt signals are 
transduced  to the downstream β-catenin signaling cascade through Frizzled 
(FZD) family receptors and LRP5/LRP6 coreceptor [35, 36]. Noncanonical 
Wnt signals are transduced through FZD family receptors and coreceptors to a 
variety of Dishevelled- or Ca
2+
-dependent signalling cascades, regulating 
processes such as convergent extension and planar cell polarity in vertebrates, 
and the polarity of hairs, bristles and ommatidia in Drosophila [34, 37]. In the 
context of gastrulation, studies have shown that the posterior expression of 
certain Wnt ligands and Wnt signaling components is indispensable for the 
formations of primitive streak, anteroposterior polarity and mesoderm [38-40]. 
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In vitro, local activation of  the Wnt pathway can induce the anteroposterior 
polarity establishment in the embryoid body (EB), which is a 3D aggregate 
formed in suspension by pluripotent stem cells. It can help to form a primitive 
streak-like region within the EB, and promote regional mesoendoderm 
differentiation [41]. This local activation of Wnt signaling requires external 
signals but is self-reinforcing after initiation [41].  
FGF2 is also essential in mesoendoderm formation during gatrulation. It 
sustains Nanog through the MEK-ERK pathway, and switches BMP4-induced 
hPSC differentiation outcome from extraembryonic lineages to mesoendoderm 
[42]. FGF signalling also regulates morphogenetic movement at the primitive 
streak [43]. 
To sum up, Nodal signalling, Wnt signalling and FGF signalling are all 
essential for mesoendoderm formation and correct morphogenetic movements 
during gastrulation. Once Nodal is activated during blastula, it can activate 
Wnt which can inversely concentrate more Nodal. On the other hand, Nodal 
can also be maintained and concentrated by BMP signals. Once Wnt signalling 
is activated either by Nodal or other external signals, it can be self-reinforcing. 
FGF signalling is essential for switching BMP4-induced differentiation from 
extraembryonic lineages to mesoendoderm during gastrulation. 
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2.1.3 Mechanical control in cell fate determination and 
morphogenesis during gastrulation 
Apart from biochemical signalling, recent studies have also shown an 
indispensible role of mechanical signalling in embryogenesis, especially 
during gastrulation [44]. This mechanical signalling is not only critical in cell 
fate determination such as mesoendoderm differentiation, but also 
indispensible for the various morphogenetic movements occurring during 
gastrulation. In amphibian embryos, the coordinated and differently located 
morphogenetic movements during gastrulation are believed to be mediated by 
biomechanical interactions between different parts of a gastrulating embryo 
[44, 45]. Series of Drosophila embryos studies also demonstrate a critical role 
of mechanical signalling in gastrulation such as cell sorting [46, 47], germ 
band extension [48, 49], anterior midgut differentiation [50], and 
mesoendoderm differentiation [51].   
Farge (2011) suggests that mechanical signals actually can pattern gene 
expression within the developing embryo, therefore inducing the following 
morphogenetic movement sequence [52]. Morphogenetic movements require 
correctly patterned gene expression. For instance, mesoderm invagination in 
Drosophila embryos during gastrulation requires the transcription factor Twist, 
and the expression of Fog and Snail in the mesoderm [51, 53]. In fact, there 
are two waves of constriction occurring in the apical ventral cells which lead 
to Drosophila mesoderm invagination. The first wave is a Snail-dependent 
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stochastic process, whereas the second wave is controlled by Twist and 
requires Fog protein [51]. Twist expression is found to be mechanically 
induced by stomodeal cell compression due to germ-band extension during 
endogenous development [50, 54].  
In order to understand how mechanical signalling controls the gene 
expression and apply it for basic and clinical research, a lot of in vitro cell-
based studies other than embryo studies have been done. One major part of 
these studies is related to how mechanical signals affect cell fates under same 
biochemical induction environment. For instance, matrix elasticity and 
geometric cues can direct mesenchymal stem cell (MSC) lineage specification 
[55-57].  Naive single MSCs can sense the elasticity of the matrix and become 
neurogenic, myogenic or osteogenic when sitting on soft (0.1-1kPa), stiffer (8-
17 kPa) and rigid (25-40 kPa) matrices respectively [55]. Geometric shapes 
which can increase cytoskeletal tension of single adherent MSCs promote 
osteogenesis relative to adipogenesis [57]. Two studies also show the critical 
role of mechanical gradients in spatial patterning of cells into specified 
lineages at appropriate locations [58]. In the presence of soluble factors 
inducing both osteogenic and adipogenic differentiation, MSCs at the edge of 
multicellular islands corresponding to regions of high mechanical stress 
differentiated into the osteocytes, while those in the centre which corresponds 
to low stress became adipocytes [58]. Similarly, gradients of mechanical stress 
within multicellular islands of mouse mammary epithelial cells (SCp2) can 
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define the spatial locations at which EMT occurs [59]. EMT is a phenotypic 
change in which epithelial cells lose their cell polarity and cell-cell adhesion 
and become migratory and invasive mesenchymal cells. It is important for 
early cell differentiation and collective cell migration during morphogenesis 
[26, 60-62]. When treated with transforming growth factor (TGF)-β, cells 
within regions of highest mechanical stress such as colony edges and corners 
expressed EMT markers, whereas those in the centre did not [59].  
In summary, while biochemical cues are essential for stem cell 
differentiation, mechanical signalling is also critical in spatially defining cell 
fates both in vitro and in vivo. At the same time, it is also indispensable for 
morphogenetic movements induction during development such as gastrulation. 
Current in vitro studies related to spatial cell fate control are most done in 
MSCs or adult mammalian cells, no hPSC-based studies are available. Due to 
the cell property differences between MSCs/adult mammalian cells and hPSCs 
which may lead to different underlying mechanisms, studies on hPSCs are 
needed to study the effects and mechanisms of mechanical signalling in early 
hPSC differentiation. In addition, no in vitro studies to date have shown the 
role of mechanical signalling in morphogenetic movement control in the 
context of stem cell differentiation. Therefore, a hPSC-based model showing 
the dual role of mechanical signalling would be most helpful to recapitulate 
and study human embryogenesis. 
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2.2 Developmental toxicity 
After knowing the basics of mammalian development and embryogenesis 
in Section 2.1, this section enters into the developmental toxicity testing field. 
It first gives a clear definition of developmental toxicity, then follows the 
introduction of in vivo animal studies for developmental toxicity testing, 
which are still the most widely accepted methods so far.  
2.2.1 Birth defects and developmental toxicity 
Major birth defects are conditions present at birth that cause structural 
changes in one or more parts of the body, which have a serious, adverse effect 
on health, development, or functional ability of the body. In United States, 
birth defects are one of the leading causes of infant death, accounting for more 
than one in every five infant deaths [63, 64]. In Singapore, birth defects 
constituted 13.6% of population stillbirths, 25.2% of population perinatal 
mortality, and 45.7% of population neonatal mortality between 1994 and 2000 
[65]. In addition, babies born with birth defects have a greater chance of 
illness and long term disability than babies without birth defects. Birth defects 
actually occur before a baby is born, and most occur in the first 3 months of 
pregnancy, which is a very important stage of development when organs of the 
baby are forming. 
Xenobiotics may cause developmental toxicity, which is the adverse 
effects on the developing embryo or fetus, resulting in severe birth defects. 
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Xenobiotics are chemicals which are found in an organism but not normally 
produced or expected to be present in it, or substances which are present in 
much higher concentrations than usual. In presence of xenobiotics such as 
certain drugs, deviant development may happen due to their teratogenicity, 
such as death, malformation, growth retardation, and functional deficiency. 
The manifestations of these deviant development increase in frequency and 
degree as dosage increases, from the no-effect to the totally-lethal level [1]. 
Potential Mech Developal toxicity of compounds include mitotic interference, 
altered membrane function/signal transduction, altered energy sources, 
enzyme inhibition, altered nucleic acid synthesis and mutations, as well as 
perturbations in gene or protein expression and programmed cell death [66]. 
In order to correctly classify those xenobiotics which may cause 
developmental toxicity to human, different drug screening methods, including 
both in vivo and in vitro models, have been developed. In vitro models mainly 
use cells or animal embryos as the experiment materials. Due to the 
complexity of embryo development, these models so far could only 
recapitulate some major developmental events within certain critical phases 
during embryogenesis. Therefore, in vivo animal studies are still the most 
commonly applied methods to date.  
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2.2.2 In vivo animal studies for developmental toxicity testing 
The application of in vivo animal studies for human teratogen screening is 
based on a series of assumptions [1]. One of the key assumption is that an 
agent which can cause developmental toxicity to the tested animals will 
potentially pose a hazard to humans as well. However, the types of effects 
seen in animals are not necessarily the same as those may be seen in humans. 
This could be due to the inter-species variations in critical periods, timing of 
exposure, metabolism, developmental patterns, placetation, or mechanisms of 
action. Because of these existing differences, the most appropriate species 
should be used when applicable. The rat or the rabbit are normally the 
preferred species for developmental toxicity testing to date unless other 
species are considered as more relevant for certain xenobiotics. Usually 
animals are treated with test chemicals during pregnancy, and different 
toxicity endpoints, such as litter size, fetal weight, prenatal mortality, sex ratio 
as well as different malformations, are evaluated shortly before parturition.  
There are different readout parameters in animal studies. Normally the no 
observable adverse effect level (NOAEL) and the lowest observable adverse 
effect level (LOAEL) are identified based on statistical tests as well as their 
biological significance. Appropriate dose selection is very important to make 
these two endpoints meaningful. Another readout is the benchmark dose 
(BMD), which is defined as the lower confidence limit on a dose that produces 
a particular effect size (e.g. 1%, 5% or 10% change compared with the 
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controls) and calculated by mathematical modelling. This BMD approach 
makes use of the entirety of the data and accounts for data variability.  
The advantage of in vivo animal studies using either rodents or non-
rodents compared with all in vitro developmental toxicity testing platforms are 
quite easy to interpret. First, it can test the adverse effects of compounds 
throughout the whole cycle of offspring development. Second, in the presence 
of placenta, it has similar compound adsorption, distribution, metabolism and 
activation capacity as human. However, the disadvantages of using in vivo 
models are quite obvious at the same time. First, in vivo models are quite 
expensive, need long experiment cycle, and more importantly, require a large 
number of animals for testing [2]. Second, for abnormal embryo development 
observed in the presence of maternal toxicity, it’s difficult to rule out the 
possibility that the abnormality is due to indirect maternal toxicity instead of 
developmental toxicity of the compound [67]. Last but not least, the existence 
of high inter-species variation (~40%) in developmental toxicity response 
limits the accuracy of prediction for all in vivo studies [3, 4]. Simply adding a 
second species for compound testing will lead to higher false positive rates 
(40-60%) [68].  
2.3 In vitro animal-based models for developmental toxicity testing 
Despite the advantages of in vivo animal models introduced above, the 
need to reduce animal consumption, testing time and cost associated with in 
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vivo models have galvanized the development of alternative in vitro models. 
Before hPSCs were successfully derived in 1998 [11], main in vitro animal-
based drug screening platforms for developmental toxicity testing include the 
frog embryo teratogenesis assay (FETAX) on xenopus [5], the chicken 
embryo toxicity screening test (CHEST) [6], the micromass (MM) assay using 
mouse embryonic mesenchymal cells [7], the mammalian whole embryo 
culture (WEC) assay using mouse [8] or rat, the zebrafish developmental 
toxicity assay [9], and the mouse embryonic stem cell test (mEST) [10]. 
According to the ECVAM Scientific Advisory Committee (ESAC), only MM 
assay, WEC and mEST for embryotoxicity testing are scientifically validated 
using twenty chemicals of known teratogenicity and ready for consideration 
for regulatory acceptance and application [69-71]. The accuracies of the three 
assays were 80% for WEC, 78% for mouse EST and 71% for the MM assay. 
The zebra fish model, on the other hand, has recently been proven to have 
comparable screening performance compared with all the above three assays 
[72-74]. In the following part of this section, I will introduce these four in 
vitro animal-based assays. The protocols, main applications as well as 
advantages and drawbacks will be covered for each of the assay. 
2.3.1 The MM assay 
The rodent micromass (MM) assay is based on the technique developed 
by Umansky to study the development and differentiation of chick embryo 
limb cells [75]. When cultured at high density (micromass), limb bud 
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mesenchyme cells isolated from 13-day rat embryos will form foci of 
differentiating chondrocytes [76], a fundamental step in the morphogenesis of 
the skeleton (Fig. 2.3.1). The MM assay can identify particular teratogenic 
compounds which can disrupt this cartilage histogenesis. The number of foci 
and the total surface of foci are calculated after compound treatment. The 
concentrations that produced 50% inhibition (IC50) are then identified and 
used for the compound classification. Based on the results of the ECVAM 
validation study, the MM assay has a relatively good accuracy of prediction 
(70%) in general, with a best performance in identifying strongly teratogenic 
compounds [69]. However, currently studies using the MM assay for 
developmental toxicity screening are quite limited, possibly due to its 
laborious nature and the use of animal embryos.   
 
 
Figure 2.3.1 Schematic representation of limb bud cell preparation. Limbs are 
dissected from the embryo, trypsinized into single cell suspension, plated at 
high density (micromass) and flooded with medium. (Adapted from [76]) 
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2.3.2 The WEC assay 
The rat whole embryo culture (WEC) technique was mainly developed by 
Denis New in the 1960s [77]. The rat or mouse embryo and amnion enclosed 
within the visceral yolk sac (VYS) are explanted intact and cultured in an all-
liquid media consisting mainly of heat-inactivated rat serum. A defined gas 
mixture is provided to the culture, whose oxygen content increased as a 
function of embryo age [77]. To drive more oxygen into the embryos, the 
whole culture system is in roller bottles, which can provide continuous 
turnover of the gas-liquid interface [78]. Morphological scoring system is 
applied to evaluate the development of the postimplantation embryos. 
In the field of developmental toxicology, the enduring studied using WEC 
is mainly due to its flexibility [79]. It can be used for identification of a wide 
range of teratogenic agents including both chemicals and physical factors such 
as hyper/hypothermia [80] and oxidative stress [81]. By adding a metabolic 
activation system [82], or culturing embryos in serum obtained from animals 
even humans dosed in vivo [83, 84], WEC can also identify proximate 
teratogens whose toxicity are due to their metabolites instead of themselves 
without knowing the exact metabolic pathways. In addition, WEC could also 
be applied in rabbit other than rat or mouse, which can be used together with 
rat WEC to study the mechanisms underlying discordant responses between 
these two species (Fig. 2.3.2). Last but not least, the WEC could also be used 
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to study the in vivo-in vitro correlations of the developmental toxicity 
responses [85].   
Figure 2.3.2 Embryos showing range of development possible in WEC. A: 
Gastation day (GD) -9 rat embryo. epc, ectoplacental cone; a, allantois; emb, 
embryo; ys, visceral yolk sac. B: GD-12 rat embryo in enclosed visceral yolk 
sac. C: GD-12 rat embryo with visceral yolk sac removed.h, heart; lb, limb 
bud. (Adapted from [79]) 
Despite the various advantages it could offer in developmental toxicology 
studies, WEC still suffers from some drawbacks. First of all, it uses animal 
embryos as the experiment objects, and the serum required to culture the 
embryos still need to sacrifice a lot of animals. Secondly, WEC is low 
throughput compared with the mouse EST and the zebrafish model, which 
makes its application for early screening quite limited. Thirdly, although the 
rat WEC could be used together with rabbit WEC, it still remains the question 
regarding human relevance of animal data, which exists in all animal-based in 
vivo and in vitro models. 
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2.3.3 The zebrafish model 
The zebrafish model is a popular vertebrate model for developmental 
biology studies and toxicity screening of environmental contaminants as well 
as  pharmaceutical compounds. It has several experimental advantages, such 
as the transparency of  embryo and larva, test period, low cost, as well as easy 
manipulation [86]. The zebrafish finishes its embryogenesis in 72 hr, and can 
develop discrete organs and tissues in 120 hr after fertilization [87]. For 
developmental toxicity screening, the zebrafish embryos are exposed to test 
compounds with multiple concentrations for certain time period, which usually 
varies from 6-8 hr to 144 hr after fertilization, and evaluated for death and 
abnormal morphological changes [74, 88, 89] (Fig. 2.3.3). A morphological 
scoring system is applied with a score of 5-0.5. Score of 5 indicates normal 
morphology, while score of 1 represents severe malformations and score of 
0.5 represents missing structures. The LOAEL and NOAEL values are 
identified together with the concentration of test compound which results in a 
25% lethality rate (LC25). The LOAEL corresponds to a morphological score 
of no more than 3, and the NOAEL corresponds to a morphological score of 4. 
Compound with LC25 to NOAEL ratios of 10 or greater will be classified as a 
teratogen.  
Currently studies using zebrafish models for developmental toxicity 
testing generally showed an accuracy of 83-87% [73, 89, 90]. However, one 
study published in 2011 only showed an accuracy of 60% when testing 15 
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compounds of known teratogenicity [91], which raises the necessity of further 
improvement and validation of the current model. It also has limitations 
compared to in vivo animal studies using mammals. Despite comparable 
development processes, the phenotypic differences between zebrafish and 
mammals are quite obvious, making it difficult to correlate abnormalities 
observed in zebrafish with those in mammals. More importantly, the lack of 
placenta makes the exposure to drugs from indirect to direct, leading to 
potential differences in drug adsorption, distribution, adsorption, distribution, 
metabolism and activation capacity compared with mammals.  
 
 




2.3.4 The mEST 
The core standard of mEST is to evaluate the toxicity of compounds based 
on their effect on mouse embryonic stem cell (mESC) differentiation to 
beating cardiomyocytes [10]. The assay is based on the fact that in the 
presence of fetal bovine serum (FBS) and absence of the leukemia inhibitory 
factor (LIF) in the maintenance medium, majority of the mESCs would 
spontaneously differentiate into cardiac lineage. According to the standard 
protocol, the mESC line D3 cells are first formed into embryoid bodies (EBs), 
which are multicellular aggregates of cells, using hanging drop method (Fig. 
2.3.4). These EBs are harvested on day 3 and kept in suspension culture for 2 
days before seeded into 24-well plates for further outgrowth and 
differentiation. Drug dosing starts at the very first beginning of EB formation 
and continues until the end of the cell culture. On day 7 or day10, all the cells 
would be accessed for cardiac differentiation either using FACS to check the 
cardiac gene expression levels or using traditional microscope observation, 
and an 50% of inhibition of differentiation (ID50) value would be acquired for 
each test compound. Together with the 50% of inhibition of cytotoxicity (IC50) 
values of each drug for mESCs as well as mouse embryonic fibroblast cell line 
3T3 cells, they could classify the test compounds into three classes as "non-
embryotoxic", "weakly embyotoxic" and "strongly embryotoxic" using the 




Figure 2.3.4 Different time points in cardiac differentiation of mESCs. (a) 
Undifferentiated mESCs cultured in maintenance medium in the presence of 
LIF. (b) Hanging drop culture from day 1 to 3 of differentiation. (c) Embryoid 
body at day 5 of differentiation in suspension culture. (d) Embryoid body 
outgrowth at day 10 of differentiation in 24-well plates. The center of the 
picture in d shows the area at which beating cardiomyocytes were located. 
(Adapted from [10]) 
Although mEST has been validated by ESAC, there are still many 
limitations and disadvantages of this assay [10]. The whole test spans 7 or 10 
days, which is relatively long, and the differentiation process is quite labour-
intensive. One of the main limitations is the high inter-species variation (~40%) 
[3], which means toxicity tests using animals are not representative for human 
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beings due to species-specific pharmaco-toxicological responses, and also 
exists in all of the other methods listed earlier. Famous examples have been 
shown in the cases of thalidomide [92], 13-cis retinoic acid and isotretinoin, 
which all demonstrated no obvious effects in mice but led to severe 
malformations in human embryos [93, 94].  
Besides inter-species variation problem, a recent study using the mEST 
showed that the moue EST could only identified two out of thirteen substances 
tested, resulting an accuracy of only 15% [95]. None of the thirteen chemicals 
have inter-species variation in developmental toxicity between mouse and 
human. A further detailed study on these eleven misclassified compounds 
found that the lack of other endpoints such as developmental neurotoxicity and 
osteotoxicity might be the cause of misclassification for seven of these drugs 
[96]. The application domain of the mEST was limited to compounds that 
function in cardiac development and do not need metabolic conversion [96]. 
2.4 In vitro hPSC-based models for developmental toxicity testing 
Since human embryonic stem cells (hESCs) were successfully derived 
from human blastocysts in 1998 [11], people are trying to replace mESC with 
hESCs in developmental toxicity testing in order to avoid inter-species 
variation [94, 97]. Also, the generation of induced pluripotent stem cells 
(iPSCs) from human adult cells [98] has provided more and cheaper cell 
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sources for compound testing, and made it possible to study patient-specific 
drug responses.   
Up to now, few assays using hPSCs (hESCs & iPSCs) for developmental 
toxicity testing have been developed to screen a wide range of teratogens. The 
metabolite biomarker-based hPSC teratogenicity assay [99] and the human 
pluripotent stem cell test (hPST) [100] are probably the only two most 
promising ones. In the following sections, I will first introduce these two 
assays in more detail, and then summarize the main advantages and limitations 
of current hPSC-based models for developmental toxicity testing.  
2.4.1 The metabolite biomarker-based hPSC teratogenicity assay 
Currently the most developed assay using hPSCs should be metabolite 
biomarker-based hPSC teratogenicity assay. It’s first developed in 2010 by 
Stemina Biomarker Discovery, Inc. and kept being optimized afterwards [13, 
99, 101]. Basically they cultured the WA09 hESCs in undifferentiated state 
during compound exposure of 72 hrs, and collected the spent media from the 
last 24-hr treatment for liquid chromatography high resolution mass 
spectrometry (LC-HRMS) analysis. Various metabolites were then recognized 
by mass feature detection and targeted metabolite biomarkers were identified 
as indicators of developmental toxicity. In their study, by using two metabolite 
biomarkers ornithine and cystine, which are indicators of polyamine 
metabolism and reactive oxygen species (ROS)-related pathways, they could 
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classify the potential teratogens in the test set (13 drugs) with 77% accuracy 
[99]. Together with the training set data, the classification accuracy could be 
as high as 89% with 36 drugs tested.  
 
Figure 2.4.1 Graphical representation of the classification scheme for known 
human teratogens and nonteratogens utilizing the therapeutic Cmax 
concentration to set the classification windows. The dose-response curve for 
the o/c ratio (purple curve) was fit using a four-parameter log-logistic model 
and used to interpolate the concentration where the o/c ratio crosses the 
teratogenicity threshold (i.e., teratogenicity potential, black-bordered red 
circle). A test compound was predicted as a nonteratogen when the 
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teratogenicity potential concentration is higher than the human therapeutic 
Cmax (A). A test compound was predicted as a teratogen when the 
teratogenicity potential concentration is lower than the human therapeutic Cmax 
(B). The x-axis is the concentration (μM) of the compound. The y-axis value 
of the o/c ratio is the ratio of the reference treatment normalized (fold change) 
values (ornithine/cystine) (Adapted from [99]) 
The above figure shows how this assay classified individual 
developmental toxicants. They used the ornithine/cystine ratio (o/c ratio), 
which is the fold change of ornithine for treatment x divided by the fold 
change of cystine for treatment x, as the experiment readout. A teratogenicity 
threshold of 0.88 was set to this ratio. If the exposure levels are greater than 
the concentration corresponding to the teratogenicity threshold, which is called 
the teratogenicity potential concentration, the treatment would be considered 
as teratogenic (Fig. 2.4.1). After that, the teratogenicity potential concentration 
was compared with the peak plasma in vivo concentration (Cmax) of the test 
compound. If the teratogenicity potential concentration is lower than Cmax, the 
test compound would be classified as a teratogen; otherwise it would be a non-
teratogen.  
One of the main advantages of the metabolite biomarker-based hPSC 
teratogenicity assay is that it can detect human teratogenicity of chemicals at 
their Cmax following therapeutic doses, which is considered to be more 
clinically relevant. In addition, this assay has the highest accuracy (89%) for 
the same set/subset of test compounds when compared with most of the 
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animal-based in vivo and in vitro assays such as rodent (86%) and rabbit (79%) 
in vivo assays, as well as mEST (74%), WEC (73%) and the zebrafish model 
(75%) [99]. In addition, this assay might also be used to understand the Mech 
Developal toxicity of certain compounds. Last but not least, the metabolite 
biomarker-based hPSC teratogenicity assay is high-throughput, as well as time 
and cost-effective. 
However, the metabolite biomarker-based hPSC teratogenicity assay may 
still suffer from several drawbacks. First, all the hPSCs were cultured in 
maintenance medium without any differentiation, compounds which adversely 
affect differentiation into specific lineages may not be correctly classified. For 
example, Diphenylhydantoin and Bosentan, which of both could disrupts the 
cardiovascular and craniofacial development in human, were misclassified as 
non-teratogens using the metabolite biomarker-based hPSC teratogenicity 
assay [99]. Second, no spatial and morphological endpoints were included, 
primarily due to no spatial and temporal control of the culture system. Besides, 
by only using the o/c ratio as the model readout, the model may be most 
applicable in finding compounds which could disrupt the ROS-related 
pathways and polyamine metabolism.  
2.4.2 The hPST using mesoendoderm differentiation 
The human pluripotent stem cell test (hPST) was developed by Hoffman-
La Roche in New Jersey in 2013, which evaluated compounds’ teratogenicity 
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in the context of mesoendoderm differentiation of hPSCs [100]. The whole 
test was done in monolayer cell culture condition in a 96-well plate format, 
and the cells were differentiated in a chemically-defined media for 3 days 
before fixation and immunostained for mesoendoderm markers for data 
analysis (Fig. 2.4.2a). The concentration of the test compound which could 
result in 50% inhibition of endoderm marker Sox17 expression relative to 
DMSO control, i.e. IC50 of Sox17, was calculated for each compound. By 
applying a IC50 threshold of 30 μM, the hPST could acquire an accuracy of  94%  
in screening of 71 pharmaceutical compounds (Fig. 2.4.2b). If changing the 
threshold from 30 μM to 35 μM, it could correctly classify 13 of 15 




Figure 2.4.2 The hPST model (a) Schematic figure showing the time line of 
mesendoderm differentiation, compound dosing, and immunostaining. 
(Adapted from , Fig. 2a). (b) Plot of SOX17 and DAPI IC50 values for 71 
tested pharmaceutical compounds. The colored boxes on the x-axis delineate 
the compounds tested. Boxes in red are true positives, blue boxes are true 
negatives, and yellow boxes are incorrectly classified at the 30μM SOX17 
IC50 threshold. (Adapted from [100]) 
Although the hPST has been shown a high accuracy in compound 
screening, it still need further improvement in several aspects. First, the assay 
so far only has different test sets of compounds without any application sets. 
The thresholds shown here are kind of artificial without further validation. No 
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explanation was given regarding the inconsistency of IC50 thresholds between 
pharmaceutical compounds and environmental toxicants. Second, the quality 
control of the hPST assay is not trivial due to stochastic factors involved in 
hPSC differentiation or inherent passage-to-passage variation. The failure rate 
of a 96-well plate was near 20% even after fully optimization and quality 
screen of frozen cell stocks. In addition, when changing the hPSC line from 
current H9 to other hPSC lines such as LSJ-1, the concentration as well as 
duration of growth factor treatment for differentiation must be recharacterized 
due to line-to-line variability.  
2.4.3 Summary 
Despite of various aspects required for further development, it’s kind of 
surprising that hPSC-based assays could actually show a decent accuracy 
(~90%) of developmental toxicity testing so far by only focusing on 
undifferentiated maintenance culture or the early stages of organogenesis since 
embryo development is so complex. There are some possible supporting bases 
behind it. First, the elimination of inter-species variation existing in all animal-
based in vivo and in vitro assays improves the accuracy of all hPSC-based 
assays. Second, hPSCs are derived from human embryo and capable of 
differentiation into every cell type in the body. This broad transcriptional 
competence allows the interrogation the broadest milieu of signalling 
pathways when early stages of differentiation were captured [100]. Lineage-
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specific differentiation may limit an assay’s capability in predicting 
developmental toxins which affect development of a different lineage [99].    
The hPSC-based assays can be best used in early discovery-phase 
detection of potential teratogenic xenobiotics due to their human-specific, 
high-throughput, time and cost-efficient features. Focusing on early stages of 
embryo development in developmental toxicity testing significantly reduces 
the time duration of  in vitro hPSC-based assays from one week to 3 days 
without sacrificing the assay accuracy. However, current hPSC-based assays 
still need further optimization and validation. More importantly, these models 
only focus on the differentiation capabilities of hPSCs without considering the 
indispensible spatial and temporal control of cell differentiation and 
morphogenesis during embryo development, which was mentioned in Section 
2.1. Therefore, new hPSC-based models are needed to recapitulate this 
important feature during early embryo development, which may show a higher 
predictivity for teratogen screening. 
3. Specific aims 
As mentioned in Chapter 2, cell differentiation and tissue morphogenesis 
characterize the whole embryo development process. The correct embryo 
development needs not only the correct cell fate control, but also needs the 
correct spatial control within the embryo. However, current in vitro hPSC-
based models for developmental toxicity testing are all established based on 
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differentiation or maintenance culture-only platforms without any spatial 
control of the differentiation. In addition, no specific morphogenetic 
movements have been captured. Here, we hypothesize that a new hPSC-based 
model which captures both spatial controlled cell differentiation and 
morphogenetic movements may be more sensitive to teratogen treatment and 
show a better prediction performance compared with existing in vitro models.  
In order to establish such a model, the mechanism behind the spatial 
controlled differentiation and morphogenesis needs to be studied and applied. 
Studies have shown that while biochemical cues are essential for stem cell 
differentiation, mechanical signalling is actually critical in spatially defining 
cell fates in vivo. However, so far the relevant in vitro studies have only been 
done in MSCs or adult mammalian cells. Due to the cell property differences 
between MSCs/adult mammalian cells and hPSCs which may lead to different 
underlying mechanisms, studies on hPSCs are needed. 
Once this new hPSC-based model which captures both spatial controlled 
cell differentiation and morphogenetic movements is established, its 
sensitivity to known teratogens needs to be tested. Proper data analysis is also 
needed to quantify the drug testing results and correctly differentiate 
teratogenic compounds from the non-teratogens.  
Therefore, there are three main aims presented in this dissertation: 
 1) To establish a hPSC-based spatially patterned mesoendoderm 
differentiation model and study the underlying mechanism.  
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2) To mimic both spatially patterned mesoendoderm differentiation and 
morphogenesis within the differentiation model and verify its sensitivity to 
existing developmental toxic drugs. 
3) To correctly classify drugs into teratogenic and non-teratogenic ones 
and scale up the system if possible. 
This dissertation would provide insights into the mechanism of spatially 
patterned differentiation in hPSCs, which refers to Aim 1 specifically; and 
show for the first time an in vitro model capturing both spatial differentiation 
patterning and morphogenesis (Aim 2). This model opens up the mindset of 
platform designing for developmental toxicity testing application and probably 
provides a better system for more accurate and robust developmental toxicity 
screening (Aim 2 & 3). In the following chapters (Chapter 4-6), experiment 
designs and results of each aim are presented respectively.   
4. E-cadherin mediated spatial differentiation of hPSCs within 2D cell 
colony 
4.1 Introduction 
The stem cell microenvironment is a critical determinant in cell fate 
specification. A precise understanding of how different environmental cues 
affect decision rules during cell fate instruction can provide insights in 
mechanisms controlling spatially organized differentiation during actual 
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embryo development. So far, researchers have focused on how local paracrine 
signaling leads to stem cell fate heterogeneity [102, 103], as well as the effects 
of mechanical forces generated by cell adhesions in the stem cell niche on cell 
fate determinations. Asymmetry in cell-cell and cell-matrix adhesions in the 
developing embryo is known to be an important determinant for patterning 
tissues [104]. However, its corresponding role in generating heterogeneity in a 
PSC culture is currently unknown.  
Most of the current understanding on the effects of mechanical force in 
human stem cell fate specification is based on studies with adult human stem 
cells [105, 106]. Asymmetry in integrin mediated mechanical forces between 
the periphery and interior of a MSC population can spatially direct osteogenic-
adipogenic [57, 58] or chondrogenic-myogenic [107] differentiation decisions. 
However, since hPSCs are epithelial in nature, fundamental differences in 
mechanical force transmission between MSCs and hPSCs may alter the 
underlying mechanisms of cell fate instruction. Besides integrin adhesion, E-
cadherin adhesion has been demonstrated to specifically affect hPSC fates. E-
cadherin adhesion is required to maintain pluripotency [108, 109] whereas 
increased integrin adhesion-mediated forces promote differentiation [110]. 
Interestingly, the instructions of the two opposing cell fates by integrin and E-
cadherin adhesions both act through the activation of Rho-ROCK myosin II 
signaling [108-110]. This is contrary to the conventional paradigm of integrin-
cadherin crosstalk observed in adult epithelial cells (e.g., MDCK), where 
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integrin activated Rho-ROCK-myosin II signaling antagonizes E-cadherin 
activated Rho-Dia [111] or Rac [112, 113] signaling. Therefore, it is unclear 
how the two modes of cell adhesion signal through a common downstream 
effector to control hPSC pluripotency-differentiation decision; and how their 
relative spatial distribution leads to heterogeneous cell fate patterning in a 
hPSC culture.  
Here, we investigated the collective effects of integrin and E-cadherin 
adhesions in patterning mesoendoderm differentiation decision in hPSCs, 
which marks one of the earliest differentiation events in the epiblast [114].  
Cell micropattering was utilized to control and modulate the relative spatial 
distribution and strength of integrin and E-cadherin adhesions within a 
cohesive hPSC colony so as to probe their crosstalk mechanism. Our data 
indicated that E-cadherin adhesion signaling is the dominant mediator in 
patterning pluripotent-differentiation decisions. Spatially polarized integrin 
adhesion in a cohesive hPSC colony compete to recruit Rho-ROCK activated 
myosin II away from E-cadherin mediated cell-cell junctions to promote 
differentiation at that locality, resulting in a heterogeneous cell population. 
4.2 Materials and Methods 
4.2.1 hPSC maintenance and differentiation 
The hESC line H9 was obtained from WiCell Research Institute, Inc., 










 Technologies, Singapore). Mechanical scraping was 
applied during normal subculture in order to only get undifferentiated hES 
colonies after Dispase (07923, StemCell
TM
 Technologies, Singapore) 





 medium (05210, StemCell
TM
 Technologies, 
Singapore) supplemented with 100 ng/ml Activin A (338-AC-025, R&D 
Systems, USA), 25 ng/ml BMP4 (314-BP-010, R&D Systems, USA) and 10 
ng/ml FGF2 (233-FB-025, R&D Systems, USA).  
4.2.2 Fabrication of PDMS stencils for micropatterning 
Polydimethylsiloxane (PDMS) stencil components were designed with L-
edit Pro software (Tanner, USA). A laser-cutter Epilog Helix 24 Laser System, 
USA) was used to cut the designed patterns on a 127 μm thick PDMS sheet 
(Specialty Silicone Products Inc.), and then the PDMS sheet was bonded to a 
laser-cut, 2mm thick PDMS gasket using liquid PDMS and baked at 60 ℃ for 
3-4 hr to finally get the PDMS stencil for micropatterning (Fig. 4.2.1). The 






Figure 4.2.1 Generation of PDMS stencil for micropatterning. 
4.2.3 Generation of micropatterned hPSC (μP-hPSC) colonies 
The autoclaved PDMS stencil was first sealed onto a 60 mm petri dish 
using 200 μl of 70% ethanol. After drying in the cell culture hood, 450 μl 
Matrigel™ in DMEM/F12 (Life Technologies) was then added into each 
stencil and incubated for 5 hr at 37 ºC before use. To obtain single-cell 
suspension, the hPSC culture was treated with Accutase (Merck Millipore) for 
about 10 min, and the cells were resuspended in mTeSR1 supplemented with 
10 μM Y27632 (Calbiochem). The cells were seeded onto the PDMS stencils 




. For a stencil with a surface 
area of 4.5 cm
2
, 2 million cells were seeded every time. After 1 hr incubation 
for cell attachment, the stencil was removed and the unpatterned substrate was 
passivated with 0.5% pluronic acid (Sigma) in DMEM/F12. After 10 min 
incubation, the μP-hPSC colonies were washed 3 times with DMEM/F12 
(Gibco), incubated for another 4 hr in mTeSR1 medium supplemented with 10 
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μM Y27632 before switching to mTeSR1 medium. Differentiation was 
initiated after overnight incubation by changing to mesoendoderm 
differentiation medium. 
4.2.4 Immunofluorescence staining 
Samples were fixed for 20 min in 3.7% paraformaldehyde, and 
permeabilized for 15 min with 0.5% Triton X-100 in PBS. After overnight 
incubation at 4 ℃ in blocking buffer (2% BSA and 0.1% Triton X-100 in TBS 
buffer), they were incubated overnight at 4 ℃ with primary antibodies (5-10 
μg/ml in blocking buffer). The primary antibodies used in this study include: 
goat-anti-Brachyury (10 μg/ml, AF2085, R&D systems); rabbit-anti-phospho-
myosin light chain 2 (1:200 dilution, 3674, Cell Signaling); rabbit-anti-E-
cadherin (1:50 dilution, sc-7870, Santa Cruz Biotechnology); rabbit-anti-β-
catenin (1:50 dilution, sc-1496, Santa Cruz Biotechnology); mouse-anti-
paxillin (1 μg/ml, BD610052, BD BioSciences); mouse-anti-vinculin (1:200 
dilution, V4505, Sigma); mouse-anti-integrin β1 (5 μg/ml, MAB2253Z, Merck 
Millipore); rabbit-anti-Nanog (4 μg/ml, ab21624, Abcam), rabbit-anti-Fgf8 
(10 μg/ml, ab81384, Abcam), and rabbitanti-Eomes (10 μg/ml, ab23345, 
Abcam). The samples were washed 5 times with 15 min interval before adding 
the Alexa Fluor dye-conjugated secondary antibodies (1:1000, Molecular 
Probes). F-actin was stained by incubating with Alexa Fluor 488 Phalloidin 
(1:200 dilution, A12379, Molecular Probes). After 1 hr incubation at room 
temperature, samples were washed for 5 times with 15 min interval and 
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counter-stained with Hoechst 33342 (10 μg/ml, Molecular Probes) for 5 min. 
After that, samples were washed 3 times with PBS and then mounted using 
Fluorsave™ (Calbiochem). 
4.2.5 Image acquisition and analysis 
Immunofluorescence images of entire μP-hPSC colonies were acquired 
with an epifluorescence microscope (Olympus IX81, Olympus) with a 
motorized stage (Prior Scientific). Confocal images were acquired using Zeiss 
LSM 5 DUO microscope (Zeiss). Image processing and analysis was 
performed using ImageJ (version 1.46r, NIH).  
Quantification of Brachyury (T) expression 
The percentage of T
+
 cells in a μP-hPSC colony was determined from 8-
bit phase contrast and T immunofluorescence images. A region of interest 
(ROI) depicting the colony boundary was determined from the phase contrast 
image and applied to the fluorescence image, which had been subjected to 
contrast adjustment (LUT = 20-100) and binary conversion processing steps. 
The percentage of the ROI with positive fluorescence signal was measured.  
The T expression profiles in specific regions of the μP-hPSC colonies 
were obtained by defining an arbitrary line on 8-bit fluorescence images with 
adjusted contrast (LUT = 20-100), and determining the intensity profile along 
that line.  
Quantification of ppMLC expression and fiber length 
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The expression levels of ppMLC at the apical, lateral and basal 
intracellular domains were measured from a 3D confocal section spanning the 
height of the colony. The stack of confocal z-sections was divided into three 
sections to represent the apical, lateral and basal domains of the cell, and 
corresponding maximum projection images were generated. The percentage of 
ppMLC
+ 
area was determined as described above for T
+
 area quantification.  
To quantify ppMLC fiber length at different regions of the μP-hPSC 
colonies, a 8-bit projection image of a 3D confocal stack of ppMLC was 
despeckled, converted to a binary image using Otsu’s method, and subjected 
to medial axis skeletonization to obtain a morphological skeleton of the 
ppMLC fiber distribution. A ROI mask was then applied to select for the 
desired colony region to be analyzed. The fiber length was determined by 
measuring the branch length of each skeleton using the Analyze Skeleton 
plugin. The mean of the 20 longest branches was taken to be the representative 
fiber length at the particular region of the colony.  
Quantification of E-cadherin localization 
To compare the diffusiveness of E-cadherin localization within or among 
μP-hPSC colonies in different treatment groups, the average E-cadherin+ area 
per cell was quantified. A ROI of a fixed area was applied onto 8-bit 
maximum projection images of 3D confocal stacks for Hoechst 33342 and E-
cadherin, followed by image segmentation, despeckling and binarization using 
Otsu’s method to acquire the total percentage of E-cadherin+ area as well as 
 45 
 
the total cell number within each ROI. After that, the average E-cadherin
+
 area 
per cell was calculated. The higher of the average E-cadherin
+
 area per cell, 
the more diffusive of E-cadherin’s localization was within the ROI.  
4.2.6 Inhibition studies 
Monoclonal antibodies against integrin-β1 (MAB1951Z, Merck 
Millipore), -α5 (MAB1956Z, Merck Millipore), -α6 (MAB1378, Merck 
Millipore), -α2β1 (MAB1998Z, Merck Millipore) and E-cadherin 
(MAB3199Z, Merck Millipore) were used to functionally block integrin and 
Ecadherin-mediated adhesions. Goat-anti-mouse IgG (sc-2055, Santa Cruz 
Biotechnology) was used as a control antibody. The antibodies were diluted to 
desired concentrations in culture media and added during both the cell seeding 
and differentiation steps. 
For all other inhibition studies, the inhibitors were added at the initiation 
of mesoendoderm differentiation and incubated for 24 hr. Blebbistatin 
(203390, Merck Millipore) and Y27362 were used to inhibit myosin heavy 
chain and ROCK activation respectively; Cytochalasin D (C8273, Sigma) was 
inhibit the actin network; EHT1864 (3872, Tocris BioSciences) and ML141 




4.2.7 E-cadherin Fc (EcadFc)-coated substrates 
To generate μP-hPSC colonies on EcadFc-coated substrates, 10 μg/ml of 
E-cadherin Fc (648-EC-100, R&D Systems) in calcium-containing PBS was 
added to a PDMS stencil that has been sealed onto a 60 mm petri dish and 
incubated for 3 hr at 37 ℃. Cell seeding was performed as described above for 
μP-hPSC colonies on Matrigel™-coated substrate. Substrates with alternating 
strips of Matrigel™/EcadFc coating were obtained by sealing a PDMS stencil 
with 800 μm-wide strips onto a 35 mm tissue culture dish. 10 μg/ml of EcadFc 
solution in calcium-containing PBS was added to the stencil and incubated for 
3 hr incubation at 37 ℃. The stencil was then removed and backfilled with 
Matrigel™ solution to coat the remaining unpatterned substrate. After 3 hr of 
incubation, cell seeding was performed as described above. 
4.2.8 RNA isolation, cDNA synthesis and quantitative RT-PCR 
Total RNA was extracted from the samples on day 3 of the differentiation 
using the RNeasy® Plus Micro Kit (Qiagen) according to manufacturer's 
protocol. Then cDNA was then synthesized from the extracted RNA using 
High Capacity RNA-to-cDNA Kit (Applied Biosystems). To analyze the gene 
expression levels of each sample, quantitative RT-PCR was performed using 
FastStart Universal SYBR Green Master (ROX) (Roche) on the ABI 7500 
Fast Real-Time PCR system (Applied Biosystems) according to the 
manufacturer's standard protocol. The relative quantitative expressions values 
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of target genes were calculated after normalization with housekeeping gene 
GAPDH. 
4.3 Results 
4.3.1 Spatial heterogeneity in mesoendoderm differentiation 
corresponds to spatial polarization of cell adhesion and actomyosin 
networks 
Cell micropatterning has been used extensively to spatially control the 
magnitudes of cell adhesion forces within a cohesive cell population [105, 
115]. Similarly, we employed stencil micropatterning to generate circular 
hPSC colonies so as to impose polarized cell adhesions between the periphery 
and interior regions of the colony. Matrigel
™
 islands were first patterned onto 
a petri dish before single-dissociated hPSCs were seeded. The non-patterned 
area was passivated to spatially confine the cell population (Fig. 4.3.1). Cells 
in μP-hPSC colonies could maintain pluripotency and show similar gene and 
protein expression levels compared to conventionally cultured hPSCs cultured 
in mTeSR
TM
1 maintenance medium (Appendices, Fig. 9.1.1, Appendices, Fig. 
9.1.2). The colonies were cultured overnight in hPSC maintenance medium 
before mesoendoderm differentiation was initiated using a serum-free 





Figure 4.3.1 Schematic representation of micropatterning of hPSC colonies 
and mesoendoderm induction. 
To ascertain that cell adhesion and actomyosin networks were spatially 
polarized in the micropatterned-hPSC (µP-hPSC) colony, we examined the 
localization patterns of cell adhesion molecules and activated myosin II before 
differentiation was initiated (i.e., at 0 hr). We observed tissue-level spatial 
asymmetry in the distribution of the force-transmitting molecules. Integrin β1, 
vinculin and paxillin were preferentially localized to the colony periphery (Fig. 
4.3.2), suggesting stronger cell-matrix adhesions at the colony periphery than 
interior. Correspondingly, the distribution of E-cadherin was diffusive near the 
colony periphery, while their localization at the inter-cellular junctions was 
maintained at the colony interior (Fig. 4.3.3). Phosphorylated myosin light 
chain (ppMLC) was localized to a circumferential actomyosin contractile 
cable at the colony periphery (Fig. 4.3.3, white arrows). In the colony interior, 
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ppMLC was localized at the cell-cell junctions (Fig. 4.3.3). 
 
Figure 4.3.2 Asymmetric spatial localization of integrin mediated cell-matrix 
adhesion in the μP-hPSC colony. Images are immunofluorescence projections 
of 3D confocal sections of integrin β1, vinculin and paxillin before (0 hr) and 
after (24 hr) mesoendoderm differentiation. All samples were counter-stained 
for F-actin (blue). Scale bar, 20 μm. 
 
Figure 4.3.3 Asymmetric spatial localization of cell adhesion and actomyosin 
contractile networks components preceded and persisted during 
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mesoendoderm differentiation. Images are immunofluorescence staining of 
Brachyuary (T), integrin β1, E-cadherin, phosphorylated myosin light chain 
(ppMLC) and F-actin  before (0 hr) and after (24 hr) mesoendoderm 
differentiation. Inset show intensity map of T expression in the entire colony. 
Dotted white lines denote colony edge. Scale bar, 20 µm in (b), 200 µm in (b, 
inset). 
After 24 hours of differentiation, we observed positive immunostaining 
for the mesoendoderm marker, Brachyury (T) at the colony periphery (Fig. 
4.3.3, lower panel) while the colony interior remained pluripotent i.e., Nanog
+
 
(Fig. 4.3.4a). The localization of T was coincidental with the cell adhesion 
polarization patterns in the µP-hPSCs, which persisted after differentiation 
(Fig. 4.3.2, Fig. 4.3.3). 
 
Figure 4.3.4 Expression of pluripotency and mesododerm markers in μP-
hPSC colonies after 24 hr of differentiation. (a) Nanog, (b) Fgf8, (c) Eomes. 
All samples are counter-stained for Brachyuary, T (red) and nuclei (blue). 
Scale bar, 20 μm in (a-c).  
 We also observed that T
+
 cells at the colony periphery had more distinct 
intracellular apical-basal polarization of the actomyosin contractility (Fig. 
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4.3.5a). In the T
+
 cells, ppMLC expression at the apical cellular domain was 
significantly higher than that of the basolateral domains (Fig. 4.3.5c). ppMLC 
and F-actin in the T
-
 interior cells were sequestered to the cadherin adherens 
-catenin co-localization (Fig. 4.3.5a,b). Other 
mesoendoderm markers, including Fgf8, and Eomes showed similar 
expression patterns as T (Fig. 4.3.4b,c). These data collectively suggested that 
spatial localization of mesoendoderm differentiation was coincidental with the 




Figure 4.3.5 Apical-basal polarization of the actomyosin and actin 
cytoskeleton networks within μP-hPSC colonies after 24 hr of differentiation. 
(a) T
+
 cells at the colony periphery had more distinct apical-basal intracellular 
polarization of actomyosin and F-actin cytoskeleton networks. Co-
immunostaining of T (red), ppMLC (green) and F-actin (blue) shows their 
respective intracellular localization at the colony periphery and interior. White 
arrows denote circumferential actomyosin contractile cable. (b) Co-
immunostaining of ppMLC (green), β-catenin (red) and F-actin (blue) 
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showing their respective subcellular localization at the periphery and interior 
of the µP-hPSC colonies. Scale bar, 20 µm in (a, b). (c) Quantification of 
ppMLC expression at the apical, lateral and basal cellular domains of T
+
 cells 
at the periphery of µP-hPSC colonies. Data are average ± s.e.m of 7 images. 
*p<005, **p<0.01 (Student’s t-test).   
4.3.2 Control over mesoendoderm differentiation patterns by 
modulating integrin and E-cadherin adhesions 
We then demonstrate that one can modulate the relative magnitudes and 
spatial distribution of integrin and E-cadherin adhesions as a mean to control 
the ensuing differentiation process. Geometrical anisotropy of ECM substrates 
leads to a higher concentration of integrin-mediated traction forces at sharp 
corners or regions of convex curvatures [115, 116] (Fig. 4.3.6a). When the 
hPSCs were micropatterned onto Matrigel
™
 islands of different geometries at 
a constant colony area, T localization was still restricted to the colony 
periphery (Fig. 4.3.6b). By mapping T expression intensity at different 
localities within a single colony, we found that the extent of mesoendoderm 
induction was higher in sharp corners of square and rectangular colonies (Fig. 
4.3.6c) and at convex curvatures of a semi-circular arc (Fig. 4.3.6d), which 
corresponded to reported high integrin-mediated stress regions in an 




Figure 4.3.6 (a) Modulating mesoendoderm differentiation by changing the 
relative magnitude (with anisotropic geometries) and ratio (with increased 
perimeter) of integrin and E-cadherin adhesions. (b) µP-hPSC colonies of 
different geometrical shapes but same colony area. Phase images (top panel) 
and intensity maps of T expression (bottom panel) after 24 hr induction. (c) 
Average T intensity profiles (along white dotted lines in (a)) in isometric 
circular colonies or anisometric square and rectangular colonies. All colonies 
had the same area except for one of the circular colonies, which was 50% 
smaller (i.e., 50% circle). (d) Average T intensity profiles from the concave or 
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convex edges into the colony interior in a semi-circular arc, as indicated by 
white dotted lines in (a). Each intensity profile in (c-d) is an average of 16 
intensity profiles obtained from 4 colonies. (e) Percentage of T+ colony area 
in different colony geometries of the same area. Data are average ± s.e.m of 
respective sample sizes (n): circle (n=8), square (n=8), rectangle (n=7), arc 
(n=8). (f) Percentage of T+ colony area in circular colonies of different sizes. 
Data are average ± s.e.m of 8 colonies. **p<0.01 (Student’s t-test). Scale bar, 
200 µm in (b). 
While there were geometry-dependent spatial fluctuations within a colony, 
the overall extent of mesoendoderm differentiation in µP-hPSC colonies of a 
given area was not affected by their geometries (ANOVA, p=0.84) (Fig. 
4.3.6e). This may be due to the fact all the colonies had similar ratios of 
periphery-to-interior cells, which was indicated by similar perimeter-to-area 
(P/A) ratios in different colony geometries (4 – 5.8 x 10-3), and therefore were 
subjected to similar ratios of integrin and E-cadherin adhesions. Increasing the 
ratio of periphery-to-interior cells by reducing the size of colonies of a given 
geometry (i.e., having a higher P/A ratio) would increase mesoendoderm 
differentiation. When we doubled the P/A ratio for a given (circular) geometry 
by reducing the colony area by 50%, there was no change in the spatial 
distribution of T expression within the colony (Fig. 4.3.6c). However, the 
overall extent of mesoendoderm differentiation in the colony was significantly 
increased (Student’s t-test, p = 0.002) (Fig. 4.3.6f). Hence, physical attributes 
of tissue boundary, such as geometry and P/A ratio, can alter the relative 
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magnitudes or ratios of integrin and E-cadherin adhesions to affect 
mesoendoderm differentiation within a µP-hPSC colony.  
To directly demonstrate that modulating cell adhesion is sufficient to 
pattern mesoendoderm differentiation, we exogenously imposed asymmetry in 
the adhesive mode by which hPSCs attach onto a substrate. This was achieved 
by micropatterning alternating strips of Matrigel
™
 and E-cadherin-tagged with 
human Fc fragment (EcadFc) (Fig. 4.3.7a). EcadFc has been used to mimic E-
cadherin-mediated adhesion on tissue culture polystyrene substrates in a 
concentration-dependent manner [117, 118] (Appendices, Fig. 9.2.1). We first 
confirmed that hPSCs on EcadFc-coated substrates were still able to 
proliferate and maintain their pluripotency (Appendices, Fig. 9.2.2). hPSCs 
cultured as micropatterned colonies on EcadFc-coated substrate had more 
diffusive E-cadherin distribution with an appreciable increase at the basal 
domain of the cell in contact with the EcadFc-coated substrate (Fig. 4.3.7b). 
This was accompanied by a significant increase in ppMLC being sequestered 
as plaques at the basal domain of the cell (Fig. 4.3.7b,c). Mesoendoderm 
differentiation was less efficient on the EcadFc-coated substrate (Fig. 4.3.7b), 
which was consistent with previous report that EcadFc-coated substrate 
promotes ESC pluripotency [118]. Hence, the EcadFc-coated substrate could 
elicit a bona fida E-cadherin-mediated adhesive response despite the fact that 





Figure 4.3.7 Exogenously imposed mechanical polarization by 
micropatterning alternating strips of Matrigel
TM
 (MG) and E-cadherin tagged 
with human Fc fragments (EcadFc) on substrate. (a) Schematic illustrating 
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asymmetry in cell adhesion modes within a hPSC colony.  (b) µP-hPSC 
colonies on E-cadherin Fc (EcadFc)-coated substrates exhibited E-cadherin 
and ppMLC that were localized to basal domain in contact with substrate, and 
attenuated T expression. Images are confocal sections showing sub-cellular 
localization of T, ppMLC and E-cadherin after 24 of differentiation. White 
dotted line denotes colony edges. (c) Quantification of ppMLC expression at 
the apical, lateral and basal domains of cells cultured on EcadFc substrates. 
Data are average ± s.e.m of 6 images from different colonies. *p<0.05, 
**p<0.01 (Student’s t-test). (d) Immunofluorescence image of T expression on 
alternating MG-EcadFc substrates after 24 hr of differentiation. (e) T intensity 
profile along the colony edges from the MG-EcadFc interface to the respective 
adhesive substrates. The transition distance was measured as the distance 
where deviation from the plateau RFU values were >10%. Data points are 
average of 15 profiles and fitted to a 4-parameter sigmoidal model (black solid 
line). Scale bar, 20 µm in (b), 200 µm in (d). 
After micropatterning alternating strips of Matrigel
™
 and EcadFc, we 
seeded hPSC colonies and cultured them in maintenance medium for 24 hours 
before inducing mesoendoderm differentiation. Upon examining 
mesoendoderm differentiation by immunostaining for T
+
 cells, we found that 
patterns of mesoendoderm differentiation within a single hPSC colony 
corresponded to the underlying alternating Matrigel
™
/EcadFc strips (Fig. 
4.3.7d). Part of the colony experiencing integrin-mediated adhesion (i.e., on 
Matrigel
™
) maintained compact colony morphology with distinct boundary, 
and exhibited mesoendoderm patterning at the colony periphery. In 
comparison, cells in regions of the colony subjected to E-cadherin-mediated 
adhesion (i.e., on EcadFc) were more scattered and had attenuated T 
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expression. We tracked the T fluorescence intensity profile along the colony 
edges from the Matrigel
™
-EcadFc interface to the respective adhesive 
substrates. The distance over which the switch from a T
high
 region on 
Matrigel
™
 to a T
low
 region on EcadFc occurred was approximately 230 μm 
(Fig. 4.3.7e). This relatively short transition distance relative to the colony 
length scale (> 1 mm) indicated that spatial asymmetry in the substrate cell 
adhesion modes can be an effective modulator in controlling the spatial 
heterogeneity of pluripotency-differentiation fates in a hPSC culture.  
4.3.3 Spatial patterning of mesoendoderm differentiation requires 
both integrin and E-cadherin adhesions 
We next determine if integrin and E-cadherin-mediated adhesions acted in 
an independent or collective manner in generating spatial heterogeneity in 
mesoendoderm differentiation. First, we used specific integrin antibodies to 
block integrin-mediated adhesions. Attachment of hPSCs onto micropatterned 
Matrigel
™
 islands was mainly mediated by α6β1-laminin binding, while 
inhibition of α2β1-laminin/collagen or α5β1-fibronectin interactions [119, 120] 
had no significant effects on cell attachment to the Matrigel
™
 substrate 
(Appendices, Fig. 9.3.1, Fig. 9.3.3). The weakening of cell-matrix interaction 
by α6β1 antibody caused contraction of the µP-hPSC colonies in a dose 
dependent manner (Appendices, Fig. 9.3.2). For subsequent experiments, 
inhibition of integrin-mediated adhesion was performed with 0.1 µg/ml α6β1 
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antibody, where we observed a 50% decrease in colony area (Appendices, Fig. 
9.3.3).  
The localization of ppMLC to a circumferential actomyosin cable at the 
colony periphery, which was indicative of integrin adhesion generated traction 
forces, was significantly attenuated in the α6β1 antibody-treated µP-hPSC 
colonies (Fig. 4.3.8aii), whereas the cable was still present in α5β1 or α2β1 
antibody-treated colonies (Fig. 4.3.8aiv, vi). This was indicated by a 
significant decrease in the ppMLC fiber length at the α6β1 antibody-treated 
colony periphery relative to the colony interior (Fig. 4.3.8c). We observed that 
ppMLC in α6β1 antibody-treated colonies was sequestered mainly at the cell-
cell junctions both at the colony periphery and interior (Fig. 4.3.8aii). The 
inhibition of integrin-mediated adhesion was specific since the E-cadherin AJ 
network remained intact in all samples (Fig. 4.3.8a, left panel). However, 
spatial polarization of E-cadherin in α6β1 antibody-treated colonies was 
abolished. E-cadherin was localized to the cell-cell junctions at both the 
colony periphery and interior (Fig. 4.3.8ai), which was supported by a lower 
E-cadherin
+
 area per cell at both the colony periphery and interior (Fig. 4.3.8b). 
This was in contrast to a more diffusive E-cadherin localization, as indicated 
by a significantly higher E-cadherin
+
 area per cell (Fig. 4.3.8b), observed at 
the periphery of untreated (Fig. 4.3.3), α2β1 or α5β1 antibody-treated colonies 
(Fig. 4.3.8aiii, v,). The disruption of integrin-mediated adhesion in the α6β1 
antibody-treated µP-hPSC colonies abolished the polarized distribution of the 
 61 
 
cell adhesion molecules and activated myosin II, resulting in uniformly 
undifferentiated colonies, where the percentage of T
+
 area decreased to 6.4 ± 
0.5% (Fig. 4.3.9d). In α2β1
 and α5β1 antibody-treated colonies, where we did 
not observed changes in the spatial polarization of E-cadherin and ppMLC, 
there were no significant changes in the percentage of T
+
 area and their 
distribution compared to untreated colonies (Fig. 4.3.9d).  
 
Figure 4.3.8 Integrin adhesions was required to generate spatial polarization 
of actomyosin contractility and mesoendoderm differentiation. (a) E-cadherin, 
ppMLC and T localization in µP-hPSC colonies treated with (i-ii) α6β1, (iii-iv) 
α2β1, and (v-vi) α5β1 integrin antibodies. Images are immunofluorescence 
confocal images after 24 hr of differentiation. Dotted white lines indicate 
colony edges. Asterisks (*) denote periphery regions with more diffusive E-
cadherin localization as compared to colony interior. White arrows denote 
circumferential actomyosin cable. Scale bar, 20 µm. (b) E-cadherin 
localization area per cell at the periphery and interior regions of µP-hPSC 
colonies after integrin antibody blocking. A higher E-cadherin+ area per cell 
 62 
 
corresponds to a more diffusive E-cadherin localization. (c) Relative ppMLC 
fiber length between periphery and interior of colonies after integrin antibody 
blocking. Data in (b-c) are average ± s.e.m of at least 3 images from different 
colonies. *p<0.05; **p<0.01 (Student’s t-test). 
Conversely, inhibition of cell-cell adhesion by the addition of E-cadherin 
antibody resulted in scattered colonies (Appendices, Fig. 9.3.4) that were 
uniformly differentiated (Fig. 4.3.9ai-ii). The percentage of T
+
 colony area 
increased significantly to 73.6 ± 4.9% (Fig. 4.3.9d). Attenuation of cell-cell 
interaction was confirmed by a significantly more diffusive localization of E-
cadherin throughout the entire colony (Fig. 4.3.9ai,b). Colonies treated with 
unspecific IgG antibody did not affect E-cadherin localization at the cell-cell 
junctions as compared to untreated control (Fig. 4.3.9b). The localization of 
ppMLC in the E-cadherin antibody-treated colonies was diffusive throughout 
the colony and there was a concomitant loss of the circumferential actomyosin 
cable (Fig. 4.3.9aii, c). Control IgG antibody-treated colonies still retained the 
polarized distribution of ppMLC between the circumferential actomyosin 
cable at the colony periphery and cell-cell junctions at the colony interior (Fig. 
4.3.9aiv, c). This observation is consistent with that of Mertz et al, where E-
cadherin adhesion is required to reorganize and transmit integrin-adhesion 
generated traction forces to the periphery of an epithelial cell population [121]. 
Collectively, the antibody blocking experiments indicated that integrin and E-
cadherin are dependent on each other to generate spatial polarization of 
activated myosin II. Inhibiting any one mode of cell adhesion in a PSC culture 
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was sufficient to abolish this mechanical spatial polarization to achieve a 
uniform cell population.  
 
Figure 4.3.9 E-cadherin adhesion was required to generate spatial polarization 
of actomyosin contractility and mesoendoderm differentiation (a) E-cadherin, 
ppMLC and T localization in µP-hPSC colonies treated with (i-ii) E-cadherin 
antibody, (iii-iv) unspecific IgG antibody. Images are immunofluorescence 
confocal images after 24 hr of differentiation. Dotted white lines indicate 
colony edges. Asterisks (*) denote periphery regions with more diffusive E-
cadherin localization as compared to colony interior. White arrows denote 
circumferential actomyosin cable. Scale bar, 20 µm. (b) E-cadherin 
localization area per cell at the interior of µP-hPSC colonies after E-cadherin 
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antibody blocking. (c) Relative ppMLC fiber length between periphery and 
interior of colonies after E-cadherin antibody blocking. (d) %T
+
 area in the 
presence of different blocking antibodies. Data in (b-c; e-g) are average ± 
s.e.m of at least 3 images from different colonies. *p<0.05; **p<0.01 
(Student’s t-test).  
4.3.4 Integrin adhesion modulates E-cadherin adhesion signaling via 
Rho-ROCK-myosin II activity to determine pluripotency-
differentiation cell fates 
Since Rho-ROCK-myosin II signaling is implicated in both integrin and 
E-cadherin adhesions in hPSCs [108-110], the modulation of this common 
effector by pharmacological inhibitors in the μP-hPSC colonies should reveal 
whether integrin or E-cadherin functions as the dominant mechanical regulator 
in instructing pluripotency-differentiation decision. In the presence of the 
myosin motor inhibitor, blebbistatin, or the ROCK inhibitor, Y27632, at 
concentrations which did not result in significant cytotoxic effects, we 
observed that the restriction of mesoendoderm differentiation to the colony 
periphery was abolished (Fig. 4.3.10i-ii). We observed similar results when 
the actin cytoskeleton, which is required to generate actomyosin contractility, 
was destabilized with Cytochalasin D (Fig. 4.3.10iii). Inhibition of other 
GTPases, including Rac or Cdc42 by their specific inhibitors, EHT1864 and 
ML141, respectively did not affect mesoendoderm patterning (Fig. 4.3.10iv-v). 
This confirmed that Rho-ROCK-myosin II signaling was involved in 




Figure 4.3.10 Binarized images showing distribution of T
+
 cell in µP-hPSC 
colonies after 24 hr of mesoendoderm differentiation in the presence of (i) 
blebbistatin (myosin II inhibitor), (ii) Y27362 (ROCK inhibitor), (iii) 
cytochalasin D (actin polymerization inhibitor), (iv) EHT1864 (Rac inhibitor), 
(v) ML141 (Cdc42 inhibitor), and (vi) no drug treatment. Insets are 
immunofluorescence images showing T localization at colony periphery. Scale 
bar = 200 µm; scale bars in insets = 20 µm. 
We note that the concomitant loss of integrin-mediated traction forces and 
E-cadherin AJs by Rho-ROCK-myosin II inhibition (Fig. 4.3.11a) 
phenocopied the results of E-cadherin antibody blocking instead of the 
integrin-blocking experiment. Colonies treated with blebbistatin resulted in a 
significant increase in E-cadherin
+
 area per cell, indicating a more diffusive 
cellular distribution, as compared to untreated colonies (Fig. 4.3.11b). There 
was also a loss of the circumferential actomyosin cable, which was indicated 
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by a significant reduction in ppMLC fiber length at the colony periphery (Fig. 
4.3.11c). This resulted in uniformly differentiated colonies, which 
corroborated with a significant increase in the proportion of T
+
 area from 25.9 
± 3.8% in the untreated control μP-hPSC colonies to 73.6 ± 4.9% (Fig. 
4.3.11d).  
 
Figure 4.3.11 Effect of Rho-ROCK-myosin II inhibition by blebbistatin on 
mesoendoderm differentiation and patterning. (a) Immunofluorescence 
staining after 24 hr of mesoendoderm differentiation in the presence of 25 µM 
blebbistatin. (b-d) Quantitative comparison of (b) E-cadherin localization area 
per cell at colony interior, (c) relative ppMLC fiber length between periphery 
and interior colony regions, and (d) % T
+
 colony area in blebbistatin-treated 
and untreated µP-hPSC colonies after 24 hr of differentiation. Scale bar, 20 
μm in (a). 
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Our data suggested that E-cadherin-mediated signaling was a direct 
negative modulator of mesoendoderm differentiation and integrin-mediated 
signaling is likely coupled to E-cadherin-mediated signalling (Fig. 4.3.12). 
When activated myosin II was sequestered to the E-cadherin AJs, such as in 
the integrin-blocked (Fig. 4.3.8) or EcadFc (Fig. 4.3.7) colonies, 
mesoendoderm differentiation was inhibited. Conversely, the disruption of the 
AJs by E-cadherin antibody blocking (Fig. 4.3.9) or Rho-ROCK-actomyosin 
inhibitors (Fig. 4.3.10, 4.3.11) allowed for differentiation progression 
throughout the entire colony. Thus, the spatial correlation of mesoendoderm 
differentiation to regions of higher integrin-mediated adhesion was likely due 
to the corresponding destabilization of the E-cadherin AJs, and not a direct 
promotion of differentiation.  
 
Figure 4.3.12 Cartoon illustrating how polarization of cell adhesions at 
boundary of a hPSC colony differentially localizes Rho-ROCK-myosin II to 
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either actomyosin contractile or E-cadherin AJ networks to pattern 
differentiation decisions. 
4.4 Conclusion 
The interplay between integrin and cadherin adhesions and their coupling 
via activated myosin II was mainly investigated in the context of collective 
cell migration in adult epithelial cell population [117, 122]. This present study 
is to our knowledge, a first report integrating the roles of integrin and E-
cadherin adhesion-mediated Rho-ROCK-myosin II in human PSC 
pluripotency-differentiation cell fate decisions. We have shown that Rho-
ROCK-myosin II played a pleiotropic role in establishing both integrin-
mediated contractile stresses and E-cadherin AJs in the µP-hESC colonies. 
These differential functions of activated myosin II were modulated by spatial 
asymmetry in integrin and E-cadherin adhesions at the tissue boundary (Fig. 
5e). When activated myosin II was mainly sequestered to the E-cadherin AJs, 
the pluripotency circuitry persisted and cells were prevented from undergoing 
differentiation even in induction medium. At regions with increased integrin 
adhesion-mediated contractile stresses, such as at colony periphery or sharp 
corners, activated myosin II preferentially localized to the actomyosin 
contractile cable instead of the E-cadherin AJ network and the cells underwent 
mesoendoderm differentiation. Obstructing the generation of contractile 
traction force at the colony edges either by inhibiting integrin adhesion or 
employing EcadFc-mediated adhesion attenuated mesoendoderm 
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differentiation and patterning, provided that the E-cadherin AJ network is 
largely intact. A universal abolishment of both integrin-mediated contractile 
and E-cadherin AJ networks by pharmacological inhibitors of Rho-ROCK-
myosin II led to the robust differentiation of the entire colony instead, 
suggesting that E-cadherin signaling was the primary gatekeeper of 
pluripotency-differentiation decision. Hence, asymmetry in the localization of 
Rho-ROCK-myosin II resulting from spatial polarization of integrin and E-
cadherin adhesions in a hPSC colony served to provide positional cues to 
determine if a cell in a particular locality within the colony should exit from 
pluripotency and differentiate according to biochemical induction factors.  
A direct implication of this finding is that it allows for biomaterials to be 
tailored for human PSC maintenance or differentiation with minimal 
heterogeneity. In terms of hPSC model development for developmental 
toxicity testing, we could apply these spatially differentiated µP-hPSC 
colonies as the starting point of recapitulating both spatial differentiation and 
collective cell migration in vitro, and then use it for developmental toxicity 
screening. By controlling the colony size and shape, we could get a consistent 
extent of mesoendoderm differentiation at the colony periphery compared with 
unpatterned hPSC colonies. This is very important in drug screening 
application since it always needs a stable baseline to start with. Once we could 
also observe a consistent controlled collective cell migration process within 
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these colonies after further differentiation culture, we may acquire an ideal 
mesoendoderm pattern for teratogen screening. 
5. In vitro mesoendoderm pattern formation by geometrically confined 
cell differentiation and migration 
5.1 Introduction 
In order to mimic human gastrulation process in vitro, only capturing 
spatially organized mesoendoderm differentiation is not enough. Another key 
feature during gastrulation is the extensive spatially and temporally controlled 
morphogenetic movements such as collective cell migration of cell 
populations. These morphogenetic movements play critical roles in correctly 
forming embryonic structures at desired positions. Here, after the initial 
mesoendoderm induction only to the periphery of the μP-hPSC colonies as 
shown in Chapter 4, we further cultured the cells and found that these spatially 
induced mesoendoderm cells could undergo directed collective cell migration 
process and form an in vivo-like mesoendoderm pattern on day 3. The 
migration speed and the corresponding morphologic localization of the 
mesoendoderm pattern depended on the coating concentration of Matrigel. 
Despite the existence of inherent line-to-line variability, the mesoendoderm 
pattern could be formed at similar positions across different hPSC lines 
without protocol optimization.  
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5.2 Materials and Methods 
Most of the materials and methods were the same as stated in Section 4.2. 
5.2.1 Cell maintenance and differentiation 
The hESC lines H9, H1 and the iPSC line IMR90 were all obtained from 
WiCell Research Institute, Inc., (Madison, WI, USA). The cell maintenance 




Since the stock concentration of every lot of Matrigel
TM  
(354277, BD 
Biosciences, Singapore) acquired from the vendor was different, there was a 
suggested dilution factor for each lot to make consistent coating concentration 
by the vendor. We set this suggested coating concentration for hPSC culture as 
1X. To evaluate the effect of coating concentration of Matrigel
TM
 on the 
collective migration of the mesoendoderm cells, 1X, 1.5X and 2X Matrigel
TM
 
solution were used for testing. For consistently generating a mesoendoderm 
pattern at desired position and monitoring cell migration, hPSCs were cultured 
on surfaces coated with 1.5X Matrigel
TM
. 
5.2.3 Immunofluorescence staining and microscopy 
The immunofluorescence staining process was quite similar as stated in 
4.2.4. Samples were fixed with 3.7% paraformaldehyde, permeabilized with 
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0.5% Triton X-100 in PBS and incubated for 3 hr  at room temperature (RT) in 
blocking buffer (2% BSA and 0.1% Triton X-100 in PBS). After that, they 
were incubated overnight at 4 ℃ with primary antibodies (5-10 μg/ml in 
blocking buffer). The primary antibodies used in this study were as follows: 
goat anti-Brachyury (AF2085, R&D Systems), rabbit anti-Eomes (ab23345, 
Abcam), rabbit anti-Cripto1 (ab19917, Abcam), and rabbit anti-FoxA2 
(ab40874, Abcam). The samples were washed 4 times with 15 min interval 
before adding secondary antibodies (1:1000 dilution). The secondary 
antibodies used in this study were Alexa Fluor
®
 546 (A11056, Invitrogen, 
USA) and Alexa Fluor
®
 488 (A21206, Invitrogen, USA). Confocal images 
were acquired using Zeiss LSM 5 DUO microscope (Zeiss), and 
immunofluorescence images of entire μP-hPSC colonies for quantitative 
analysis were acquired using Olympus IX81 epifluorescence microscope 
(Olympus, Japan) with a motorized stage (Prior Scientific). For phase contrast 
live imaging, images were acquired every 20 min by BioStation CT (Nikon) 
using 10X objective. The imaging period started since the induction of 




5.3.1 Geometrically-confined collective cell migration in μP-hPSC 
colonies  
Our goal is to spatially organize cellular events (i.e. differentiation and 
cell migration) characteristic of embryonic development in hPSC cultures. As 
mentioned in Chapter 4, we leveraged on asymmetry in the mechanical 
environment imposed by cell micropatterning to drive differential stem cell 
fates [123]. Instead of inducing mesoendoderm differentiation for only 24 hr, 
we monitored the expression patterns of Brachyury (T), an early 
mesoendoderm marker [124], over three days (Fig. 5.3.1). T was initially 
expressed on the periphery of the colony after one day of differentiation (Fig. 
5.3.2). By day 3, the T
+ 
cells were displaced inwards by approximately 200 
μm from the colony edges, and formed an annular pattern of multilayer cells, 
suggesting that these cells underwent collective cell migration (Fig. 5.3.2).  
 
Figure 5.3.1 Schematic representation of the micropatterning of hPSC 




Figure 5.3.2  Fluorescent images of mesoendoderm marker Brachyury (T) on 
day 1- day 3. Scale bar, 200 μm.  
To verify this, a 3-day live imaging under 10X objective using phase 
contrast was performed to track the cell movements (Fig. 5.3.3). Kymograph 
analysis gave a graphical representation of spatial position changes along a 
line over the three days of mesoendoderm induction [125]. Results showed 
that after one day induction, periphery cells became motile and migrated out 
from the main colony, While T
+
 periphery cells in unpatterned hPSC colonies 
spread out from the colony continuously (Fig. 5.3.5), the physical constraints 
in the μP-hPSC colonies allowed the periphery cells to migrate outwards for 
only about ~150 µm. The majority of these motile cells then established 
contact with each other, and migrated for about 200 µm towards in the colony 
interior in an amoeboid manner on top of a cell layer in contact with the 
underlying substrate (Fig. 5.3.3). The spreading and retraction of 
 75 
 
mesoendoderm cells in the μP-hPSC colonies during the 3-day time frame was 
manifested as a major migratory front in the kymograph, which was 
consistently observed in different colonies (Fig. 5.3.4).  
 
Figure 5.3.3 Montage from a 3-day phase imaging on about one quarter of a 
circular μP-hPSC colony. Scale bar, 100 μm. 
Figure 5.3.4  Kymograph analysis showing the movement of cells along the 
yellow line shown in Fig. 5.2 throughout the 3-day live imaging time frame. 




Figure 5.3.5  Mesoendoderm differentiation in unpatterned hPSC colonies. (a-
c) Phase and fluorescent images of mesoendoderm markers for samples fixed 
on day 1 (a), day 2 (b) and day 3 (c). Scale bar, 200 μm.  
To confirm that the annular multicellular pattern is formed as a result of 
mesoendoderm cell differentiation and migration, we cultured μP-hPSC 
colonies in a basal differentiation medium without adding any mesoendoderm 
induction factors. Immunostaining results of fixed samples from day 1 to 3 
showed no detectable T expression (Fig. 5.3.6 a,b). Live imaging and 
kymograph analysis indicated that cell migration at the colony periphery was 
negligible in the absence of mesoendoderm induction (Fig. 5.3.6 c,d). Cells 
proliferated and distributed relatively evenly throughout the whole colony 
during the 3-day time frame with no annular pattern being formed (Fig. 5.3.6 
c,d). These data confirmed that the formation of an annular mesoendoderm 
pattern in the μP-hPSC colonies was specifically a result of mesoendoderm 




Figure 5.3.6 No similar annular mesoendoderm pattern formed after 3-day 




 medium. (a) Phase and fluorescent 
mesoendoderm marker T images on day 1 to day 3. Scale bar, 200 μm. (b) 
Confocal z-stack images of T and cell nuclei within a μP-hPSC colony fixed 
on day 3. (c) Montage from a 3-day phase imaging on about one quarter of a 
circular μP-hPSC colony. Scale bar, 100 μm. d) Kymograph analysis showing 
the movement of cells along the yellow line shown in (c) throughout the 3-day 
live imaging time frame.  
5.3.2 Formation of an annular mesoendoderm pattern in μP-hPSC 
colonies 
To study the annular mesoendoderm pattern formed by both 
differentiation and cell migration, a confocal z-stack analysis of the periphery 
section of a T-labeled μP-hPSC colony was performed to reveal its internal 
structure (Fig. 5.3.7). The cross section of the mesoendoderm pattern 
resembled a ridge-like multicellular structure (Fig. 5.3.7 b), where the T
+ 
cells 
were mainly localized on top of the ridge, and a narrow furrow a few microns 
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in width ran underneath the ridge (Fig. 5.3.7 a). This ridge like structure 
appeared to resemble an invagination of the epiblast sheet [126] seen during 
primitive streak formation in vivo, which is approximately an in vivo 
equivalent of the hPSCs-derived mesoendoderm cells at the multicellular ridge.   
          
Figure 5.3.7 3D structure of the mesoendoderm pattern. Confocal z-stack 
images of T and cell nuclei (a) and its 3-D reconstruction image (b) within a 
μP-hPSC colony fixed on d3. Scale bar, 30 μm in (b). 
Immunostaining of various other mesoendoderm markers was performed 
on day 3 to confirm that the migrating cells were mesoendoderm cells (Fig. 
5.3.8). The expression of mesoendoderm markers Eomes and Cripto1, as well 
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as the early definitive endoderm marker FoxA2 all co-localized with T as an 
annular pattern, indicating that the motile cells were indeed mesoendoderm 
cells (Fig. 5.3.8). Epithelial-mesenchymal transition (EMT) interrelates 
mesoendoderm differentiation and cell morphogenesis during gastrulation 
[127]. Indeed, higher expression levels of EMT markers were also detected 
within the multicellular annular pattern. Cells were isolated from the periphery 
and center of the µP-hPSC colonies on day 3 and transcription levels of EMT 
markers were determined by RT-PCR (Fig. 5.3.9). Cells in the colony 
periphery exhibited a much lower level of E-cadherin expression, and a higher 
level of N-cadherin, Vimentin and Snail compared with those in the colony 
centre (Fig. 5.3.9), indicating that EMT was also preferentially localized near 
the colony periphery together with mesoendoderm differentiation.  
 
Figure 5.3.8 Fluorescent images of mesoendoderm markers Wnt3a, Eomes 





Figure 5.3.9 RT-PCR results of EMT marker expression levels in colony 
centre and colony edge (n = 3). *, p< 0.05 in paired t-test. Inset, phase image 
showing colony edge and centre.  
5.3.3 Matrix concentration-dependent collective cell migration in μP-
hPSC colonies 
After we formed the annular mesoendoderm pattern within the μP-hPSC 
colonies, next we wanted to check whether the location of the mesoendoderm 




Figure 5.3.10 Matrix-concentration dependent collective cell migration.  
Phase and T images of μP-hPSC colonies on day 3 of mesoendoderm 
induction. Scale bar, 200 μm.  
We found that by controlling the matrigel amount coated on the dish, we 
could control the position of the mesoendoderm pattern. The recommended 
Matrigel
TM
 concentration for hPSC cell culture from the product information 
was defined as 1X. Cells were seeded on 1X, 1.5X and 2X Matrigel
TM
 coated 
surfaces. After 3 days’ mesoendoderm induction, the mesoendoderm patterns 
localized more outwards in dishes coated with higher concentrations of 
Matrigel
TM 
 (Fig. 5.3.10). In fact, cells in 2X Matrigel
TM
 coated dishes hardly 
move inwards compared those in 1X and 1.5X Matrigel
TM
 coated dishes. This 
indicated that the tag of war between cell-matrix and cell-cell interactions 
could affect the collective cell migration. With more matrix and higher cell-
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matrix interaction, cells would migration less distance. Therefore, it’s better to 
recharacterize the amount of Matrigel
TM
 solution used for coating when 
changing the lot of Matrigel
TM
.  
5.3.4 Free of line-to-line variability in mesoendoderm pattern 
formation 
As we know, hPSCs consist of hESCs and iPSCs. For each of them, there 
were different cell lines generated from different human embryos or adult cells. 
The existence of line-to-line variability may vary the mesoendoderm pattern 
formation when using a different hPSC line other than H9, and reduce the 
robustness and reproducibility of the current model [128]. Here, we wanted to 
check whether the mesoendoderm pattern formation processes observed in H9 
cells could be maintained in other hPSC lines without protocol optimization. 
Another hESC line H1 and one human iPSC line IMR90 were patterned to 
form μP-hPSC colonies and cultured in mesoendoderm induction medium for 
3 days. The expression patterns of mesoendoderm markers (T, FoxA2 and 
Eomes) were examined using immunofluorescence staining and fluorescence 
microscopy. Results showed that both cell lines could undergo spatial 
mesoendoderm differentiation at colony periphery after 1 day of culture (Fig. 
5.3.11a,d), and form a similar mesoendoderm pattern on day 3 through 
collective cell migration (Fig. 5.3.11b-c, e-f). Therefore, the formation of 
mesoendoderm pattern by geometrically confined cell differentiation and 
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migration in our μP-hPSC colonies was not cell-line specific, and could be a 
common phenomena for all hPSCs including both hESCs and human iPSCs. 
 
Figure 5.3.11 Generation of annular mesoendoderm pattern in H1 and IMR90 
cells. (a-f) 3-day phase and fluorescent images of μP-hPSC colonies formed 
by H1 cells (a-c) and IMR90 cells (d-f). Scale bar, 200 μm.  
5.4 Conclusion  
Embryo development is more than just cell differentiation. Organized 
spatial control and morphogenic movements such as collective cell migration 
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play as important roles in correct embryo formation. Here we have shown a 
first in vitro cell model which could mimic both spatially controlled 
differentiation and collective cell migration processes during embryogenesis. 
This μP-hPSC model could be used to study the underlying mechanisms of 
mesoendoderm pattern formation in human embryos, or applied for human 
teratogen detection.   
One key feature of the µP-PSC model that will facilitate its practical 
application is the consistency at which we could generate the annular 
mesoendoderm pattern, which provides a baseline to morphologically measure 
drug or other molecule-induced disruption effects. In an unpatterned hPSC 
colony, spatial patterns of mesoendoderm differentiation were heterogeneous 
and vary across cultures (Fig. 5.3.5). The use of geometric confinement by cell 
micropatterning could induce reproducible spatial patterning of 
mesoendoderm differentiation [129]. Our μP-hPSC model not only 
recapitulated spatially induced mesoendoderm differentiation, but also self-
organized collective cell migration within the colony, forming reproducible 
mesoendoderm patterns. We have shown that such annular mesoendoderm 
pattern could be generated with different hPSC lines (Fig. 5.3.11). Compared 
with other methods of creating environmental gradient to pattern stem cell 
fates, such as microfluidic patterning of soluble factors [130, 131] or 
micropatterned feeder cells [132] or hydrogels [133], the μP-hPSC approach is 
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straightforward to implement, readily scalable, and is more amenable to high 
content imaging for downstream data collection and analysis.  
6. A new method for human teratogen detection by geometrically 
confined cell differentiation and migration 
6.1 Introduction 
Teratogens are drugs or chemicals that can interfere with normal 
embryonic development and induce abnormalities in growth and functions [1], 
resulting in various birth defects. Due to the complexity of embryonic 
developmental processes, the identification of teratogens rely mostly on 
animal models [93]. However, the need to reduce the time and cost associated 
with animal testing as well as circumvent high inter-species variability (~40%) 
in teratogenic response [4] have galvanized the development of alternative in 
vitro models, especially those based on human pluripotent stem cells (hPSCs). 
The hPSC-based testing models developed so far employed temporally-
controlled differentiating stem cell cultures using either directed 
differentiation (i.e., differentiation into mesoendodermal [128], neural [16] or 
cardiac cells [14]) or random differentiation in embryoid bodies [134]. 
Measurements of molecular biomarkers by gene expression [16, 128, 134], 
flow cytometry [14], or metabolite detection [13, 99] were used to determine 
the teratogenic potential of a compound. 
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While measuring the temporal expression of molecular biomarkers, such 
as transcription factors, surface markers or secretory proteins, are fairly 
successful in predicting drug-induced toxicity on terminally differentiated 
cells [135, 136], their utility in detecting teratogenic effects of compounds has 
been limited partially due to the transient, complex and spatially organized 
nature of molecular signaling events during embryonic development. 
Therefore, a small set of biomarkers cannot adequately describe 
developmental processes. Embryonic development is characterized by spatio-
temporally regulated cell differentiation and tissue morphogenesis, which 
involves collective cell migration [20, 21]. Spatio-temporally regulated 
differentiation and morphogenesis are important in collectively forming 
developmental structures, such as the primitive streak, at the desired time and 
place during embryonic development [21], which are sensitive to disruption by 
teratogens. We hypothesize that constructing a spatial pattern of cell 
differentiation and migration in hPSC culture can provide a sensitive assay for 
detecting the teratogenic potential of compounds in vitro.  
Asymmetries in both mechanical and biochemical environmental cues 
have been shown to play important roles in the spatial patterning of cell 
differentiation and collective cell migration both in vivo [21, 50, 51, 137] and 
in vitro [57, 58, 123]. As shown in Chapter 4 and Chapter 5, we used the 
inherent mechanical asymmetry in a micropatterned hPSC (μP-hPSC) colony 
as a simple and robust means to spatially localize the mesoendoderm 
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differentiation of hPSCs and allowed them to undergo collective cell migration. 
Cells at the periphery of the colony preferentially expressed the 
mesoendoderm marker, Brachyuary (T) after one day of differentiation. These 
mesoendoderm cells underwent collective cell migration to eventually form a 
multicellular annular pattern on day 3. Here, we further applied our μP-hPSC 
model for human teratogen detection. In presence of known teratogens, the 
formation of the annular mesoendoderm pattern was disrupted in a dose-
dependent manner. Quantitative analysis of the mesoendoderm morphologic 
features across different compound treatment groups using feature clustering 
and one-way analysis of variance (ANOVA) could successfully distinguish 
known teratogens from the non-teratogens and avoid inter-species variation 
when compared with the traditional mouse embryonic stem cell test (mEST).  
6.2 Materials and Methods 
6.2.1 Cell maintenance and differentiation 
The hPSC maintenance and differentiation protocols were the same as 
stated in 4.2.1. The adult human dermal fibroblast (aHDF) was obtained from 
Lonza (Singapore) and cultured in DMEM high glucose medium (10569-010, 
Gibco) supplemented with 10% FBS and 1% Pen-Strep (09367-34, Nacalai 
Tesque). To get single cell suspension for cell seeding, the cells were washed 
with 1X PBS three times and treated with 0.25% Trypsion-EDTA (25200-114, 
Gibco) at 37 ℃ for 3-4 min.  
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6.2.2 Drug preparation 
The drugs tested in this study were Penicillin G (P3032-10MU, Sigma-
Aldrich), Thalidomide (T144-100MG, Sigma-Aldrich), VPA (P4543-10G, 
Sigma-Aldrich), D-penicillamine (P4875-5G, Sigma-Aldrich) and RA 
(554720-500MGCN, Merck, Millipore). The stocks of Thalidomide and RA 
were dissolved in DMSO (D2650, Sigma-Aldrich), while others are dissolved 
in distilled water. The dilutions of thalidomide and RA for drug treatment in 
our μP-hPSC model were prepared such that DMSO concentration was less 
than 0.25%. 
6.2.3 Cytotoxicity assay 
The cytotoxicity test was done in 96-well tissue culture plates with 100 μl 
of medium with or without the drug. For each drug, 8 concentrations with 5-
fold dilution were tested together with the vehicle controls. For H9 cells, the 
plates were coated with Matrigel
TM
  before cell seeding. 10,000 hES cells or 
500 aHDF cells were plated into each well and cultured for 3 days in the test 
solution with half change of the medium with or without the drug every day. 
On day 3, cell viability was measured using CellTiter 96® AQueous One 
Solution Cell Proliferation Assay (MTS, G3580, Promega, USA). Three 
independent tests were done for each drug to finally acquire the cytotoxicity 
results. IC25 values were acquired from either logistic regression using 
OriginPro 9 or direct reading from the cytotoxicity curve.  
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6.2.4 Image analysis  
Kymograph analysis 
      Kymographs were generated using ImageJ (Version 1.46r, NIH) with 
installed MultipleKymograph plugin. After importing the time series of μP-
hPSC colony images, an average intensity Z-projection image was generated. 
A segmented line was drawn at the region of interest (ROI) (which was the 
colony periphery in our study) in the Z-projection image and then restored in 
the original time series image window using Restore Selection Tool. After that, 
a kymograph could be generated with a line width of 1 using 
MultipleKymograph Plugin, which shows the movement of cells along the 
segmented line within time of interest. 
Morphological feature extraction 
 Morphological feature extraction from T fluorescence images was done 
in MATLAB Image Processing Toolbox (Mathworks). First, the outline of the 
μP-hPSC colony was identified by intensity difference compared with 
background and its centroid position was determined. The Otsu’s method was 
then applied to segment the whole μP-hPSC colony into T+ region and T- 
region. The relative positions/distributions of each region were acquired. All 
of the 19 morphological features were extracted based on the distribution of 
the T
+
 region, mainly including the area of the T
+
 region, relative distance of 
the T
+
 region to the colony centroid and outline, the standard deviation, 
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coefficient of variance, skewness, kurtosis, entropy and energy of the 
distribution of the T
+
 region, etc.  
Unsupervised Feature clustering 
The feature clustering was done in R (Version 3.1.2). After excluding four 
extraneous features, which showed random trends, the remaining 15 features 
were clustered into seven morphologic clusters based on their feature 
correlations by hierarchical clustering using complete linkage method. Based 
on the clustering result, the feature average values for each morphologic 
cluster were calculated and plotted in boxplots. 
6.2.5 Statistical analysis 
One-way ANOVAs were used to access the effects of test compounds on 
the morphologic changes of mesoendoderm patterns in R. Post-hoc analysis 
was performed to verify significant ANOVA results and determine DC values 
of each drug using unpaired t-test and Bonferroni correction methods. Since 
there were four test groups for each compound screening, six comparisons 
using unpaired t-test were generated. According to Bonferroni correction, the 
adjusted critical p value for 0.05 significance would be 0.05 divided by the 
total number of comparisons, which was 0.0083 (0.05/6). Therefore, the 
acquired p values by unpaired t-tests were compared with the adjusted critical 




6.3.1 Sensitivity and specificity of mesoendoderm pattern formation 
to teratogen treatment  
Since the formation of the mesoendoderm pattern in μP-hPSC colony 
encompassed developmentally relevant processes (i.e., differentiation and cell 
migration), we wanted to test if teratogens could disrupt its formation. We 
treated the μP-hPSC colonies with a paradigm teratogen, Thalidomide (800 
μM), and a known non-teratogenic compound, Penicillin G (200 ug/ml), at 
their non-cytotoxic concentrations to both hPSCs and human adult fibroblasts. 
Although T
+
 cells could be observed in both drug-treated colonies after 3 days, 
the resultant mesoendoderm patterns were distinctively different (Fig. 
6.3.1a,c). The colonies treated with Penicillin G had a similar annular 
mesoendoderm pattern to the untreated colonies, whereas the colonies treated 
with Thalidomide showed a much wider mesoendoderm pattern that was 
displaced towards the colony center (Fig. 6.3.1a,c). Live imaging and 
kymograph analysis showed that Thalidomide treatment could disrupt the 
original collective cell migration trajectory (Fig. 6.3.1d). While cells in 
Penicillin G-treated colonies underwent similar migration trajectory as that in 
untreated colonies, cells in Thalidomide-treated μP-hPSC colonies migrated 
much more towards the colony center (Fig. 6.3.1b,d). Since the tested 
concentration of both compounds was not cytotoxic to the hPSCs, the 
disruption of the collective cell migration process and the final morphology of 
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the mesoendoderm pattern by Thalidomide was likely specific to its 
teratogenic effects. Therefore, our μP-hPSC model could successfully 
differentiate teratogenic compound Thalidomide from non-teratogenic 
compound Penicillin G. 
 
Figure 6.3.1 Disruption of annular mesoendoderm pattern by teratogen 
treatment. (a,c) Fluorescent images of T in μP-hPSC colonies under Penicillin 
G (a) and Thalidomide (c) treatment after 3-day mesoendoderm induction. 
Scale bar, 200 μm. (b,d) Kymographs of cell movements around colony edges 
during 3-day mesoendoderm induction under Penicillin G (b) and Thalidomdie 
(d) treatment. Scale bar, 50 μm. 
On the contrary, it was difficult to differentiate the teratogenic effects of 
Thalidomide and Penicillin G by simply measuring the expression levels of 
molecular biomarkers for mesoendoderm differentiation. Cells from Penicillin 
G (200 μg/ml) and Thalidomide (800 μM) treated colonies as well as untreated 
control colonies were examined for the expression level of three germ layer 
markers using quantitative RT-PCR (Fig. 6.3.2). Results showed no significant 
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differences of the expression levels of both mesoendoderm markers T and Nkx 
2.5, and ectoderm markers Pax 6 and Nestin between Penicillin G-treated and 
Thalidomide-treated colonies, although colonies in both conditions had an 
increased T expression level compared with untreated controls (Fig. 6.3.2). 
Thalidomide-treated samples showed lower expression levels of two other 
mesoendoderm markers FoxA2 and Sox17 than Penicillin G-treated colonies. 
However, there were no significant differences of these two markers for either 
of these two treated samples compared with untreated colonies (Fig. 6.3.2). 
Therefore, we reasoned that measuring changes in the mesoendoderm pattern, 
which is an assimilation of multiple cellular processes, as an assay readout for 
teratogenic potential, is sufficiently sensitive and may show better specificity 
as compared to the expression levels of a panel of molecular biomarkers for 
differentiation.  
 
Figure 6.3.2 Expression levels of germ layer markers in untreated, Penicillin 
G-treated and Thalidomide-treated colonies. Mesoendoderm markers are T, 
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Nkx2.5, FoxA2 and Sox17; ectoderm markers are Pax6 and Nestin. *, p < 0.05 
in paired t-test. n= 3. 
6.3.2 A quantitative morphometric assay to classify teratogenic 
potential of compounds 
Since the annular mesoendoderm pattern in our μP-hPSC model was 
sensitive to teratogen treatment, we next developed a quantitative assay to 
measure drug-induced morphological changes to the mesoendoderm pattern, 
so as to classify whether a compound is likely to be teratogenic or not.  
The dose-dependent effect of each compound on the mesoendoderm 
pattern formation was determined by dosing at three different concentrations. 
The cytotoxicity of each compound was evaluated in order to find the 
appropriate range of testing concentrations. Since drugs or chemicals may 
have different cytotoxic effects on hPSCs and human adult cells, human 
embryonic stem cell line, H9 and adult human dermal fibroblasts (aHDFs) 
were tested for cytotoxicity of each drug. The results would represent specific 
cytotoxicity to embryonic and adult cells respectively. Based on the 
cytotoxicity data, three drug concentrations (designated as low, medium and 
high) were selected such that the lowest concentration tested was not toxic to 
both H9 cells and aHDFs, and the highest concentration should not be 
cytotoxic to aHDFs. The tested concentration was considered as not cytotoxic 
if it was less than the drug’s 25% inhibitory concentration (IC25) to the tested 
cell line [138].  
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A series of imaging processing and statistical analysis were developed to 
quantitatively measure the teratogenic effects of each drug (Fig. 6.3.3). For 
each compound, there were four test groups, consisting of zero, low, medium 
and high drug concentrations. After three days of culture in the mesoendoderm 
induction medium, immunofluorescence images of T were acquired. 
Morphologic features describing the T
+
 region within the colony were 
extracted from the immunofluorescent images using image processing. After 
excluding extraneous features, which showed random trends, the remaining 
features were clustered into different morphologic clusters based on their 
feature correlations. One-way analysis of variance (ANOVA) was then 
performed on each morphologic cluster to determine whether there were 
significant morphologic differences among test groups for each drug. If no 
significant differences among groups were identified in all feature clusters, we 
could directly classify the tested drug as non-teratogenic.  
On the contrary, if any morphologic clusters showed significant 
differences among four test groups, post-hoc analysis was then performed in 
those morphologic clusters to confirm the ANOVA results, as well as to find 
the lowest concentration showing significant mesoendoderm pattern disruption 
compared with the non-treated control group. This concentration was defined 
as the disruption concentration (DC). If DC < IC25,H9, we can infer that the 
drug is teratogenic, where it affects embryonic development without being 




Figure 6.3.3 Development of a quantitative morphometric assay for teratogen 
screening. Details are provided in the main text. DC, disruption concentration, 




6.3.3 Evaluation of the morphometric μP-hPSC model in classifying 
teratogens  
We evaluated the drug testing performance of the μP-hPSC model by 
comparing with a well-established stem cell-based assay, the mouse 
embryonic stem cell test (mEST). The mEST measures whether a drug or 
chemical can disrupt beating cardiomyocytes formation using mESCs, and is 
currently one of the leading in vitro models being validated for teratogenicity 
screening [10, 71]. Here, five drugs were selected according to the United 
States (US) FDA Pharmaceutical Pregnancy Risk Categories based on animal 
and/or human data (Table 6.3.1).  
















































*: There are five categories. Category A indicates no pregnancy risk in human,  Category B 
indicates no risk in animal studies, Category C shows positive pregnancy risk  in animals, and 
Category D & X indicate clear risks in pregnant women.  
 
Four of the drugs are classified as teratogens in vivo [92, 139-141] 
(Category D or X) while a non-teratogenic [142] drug in vivo (Category B) 
was included as a negative control. The mEST can only accurately classify 
three out of the five selected drugs (Table 6.3.1). Thalidomide affects human 
but not mouse development and therefore cannot be detected in mEST [143]. 
D-penicillamine, on the other hand, was misclassified as non-terotogenic in 
mEST [95] due to the model’s limitation in assessing only cardiogenesis 
endpoints [96]. By choosing this five model drugs, we aimed to evaluate 
whether our uP-hPSC model can potentially show better performance than the 
mEST.  
       First, the cytotoxicity data of each drug on both H9 cells and aHDFs were 
acquired to determine the low, medium and high concentrations for different 
test groups (Fig. 6.3.4). Results showed that hPSCs were more susceptive to 

























Penicillamine, exhibiting more cell death at high drug concentrations 
compared with aHDF cells (Fig. 5). In the case of RA, however, high 
concentration at about 2 µg/ml actually significantly promoted H9 cell 
proliferation whereas showed no effects on aHDFs. This is probably due to the 
fact that RA is a potent morphogen, high differentiation effects of RA which 
can induce hPSCs to differentiate into neuronal cells [144]. Thalidomide 
caused no cell death to both H9 and aHDF cells up to its highest soluble 
concentration. 
Drug dosing, mesoendoderm induction as well as immunofluorescence 
images were acquired (Fig. 6.3.5) and processed as described above. Seven 
morphologic clusters were generated by clustering the extracted fifteen 
morphologic features based on their correlations with each other (Fig. 6.3.6a). 
These seven morphologic clusters collectively describe the dispersion (CL1 
and CL3), position (CL2 and CL6), area (CL4), kurtosis (CL5) and energy 
(CL7) of the T
+




Figure 6.3.4 Cytotoxicity results of the five tested drugs. (a-e) Cell viability 




Figure 6.3.5 Fluorescent images of T in different drug test groups on day 3. 
Scale bar, 200 μm. 
 
Figure 6.3.6 Generation of morphologic clusters by feature clustering. (a) 
Hierarchical clustering of morphologic features based on feature correlations. 
Dash line indicates that 7 clusters were acquired. (b) The morphologic 
interpretations of the 7 morphologic clusters.  
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The readouts of each morphologic cluster across the four test groups (i.e. 
control, low, medium, high) were plotted for each drug and one-way ANOVA 
was performed to determine whether there were significant differences across 
the test groups (Fig. 6.3.7-6.3.11). Post-hoc analysis was performed using 
unpaired t-test and Bonferroni correction methods to verify the ANOVA 
results and determine the DC values of each drug. Our assay based on the 
morphologic clusters showed that Thalidomide, Retinoic acid (RA), D-
penicillamine, and Valproic acid (VPA) exhibited significant dose-dependent 
morphologic disruptions of the mesoendoderm pattern (Fig. 6.3.8-6.3.11). For 
each drug, at least one morphologic clusters showed significant disruption to 
the mesoendoderm pattern in the low concentration test groups (Fig. 6.3.8-
6.3.11). Therefore, the DC values for these four drugs were 30 μM for 
Thalidomide, 0.36 ng/ml for RA, 200 μg/ml for D-penicillamine, and 0.1 mM 
for VPA (Table 6.3.2). In the case of the negative control drug Penicillin G, 
ANOVA results showed no significant differences among test groups in 
almost all morphologic clusters except CL6 (p=0.0122) (Fig. 6.3.7). The high 
concentration test group at 1000 μg/ml showed a significant inward 
mesoenoderm pattern position toward the colony centre compared with zero 
dose control group (Post-hoc analysis, p=0.0014 < 0.0083) (Fig. 6.3.7f). 




Figure 6.3.7 Boxplots of morphologic cluster readout in Penicillin G test 
groups. Low: 40 μg/ml; Medium: 200 μg/ml;  High: 1000 μg/ml. *: p<0.0083 
in post-hoc analysis for comparing the difference between the corresponding 
dose group and the untreated control group.  
 
 
Figure 6.3.8 Boxplots of morphologic cluster readout in Thalidomide test 
groups. Low: 30 μM; Medium: 300 μM;  High: 800 μM. *: p<0.0083 in post-
hoc analysis for comparing the difference between the corresponding dose 





Figure 6.3.9 Boxplots of morphologic cluster readout in RA test groups. Low: 
0.00036 μg/ml; Medium: 0.0036 μg/ml;  High: 0.036 μg/ml. *: p<0.0083 in 
post-hoc analysis for comparing the difference between the corresponding 
dose group and the untreated control group. 
 
 
Figure 6.3.10 Boxplots of morphologic cluster readout in D-penicillamine test 
groups. Low: 200 μg/ml; Medium: 400 μg/ml;  High: 800 μg/ml. *: p<0.0083 
in post-hoc analysis for comparing the difference between the corresponding 





Figure 6.3.11 Boxplots of morphologic cluster readout in VPA test groups. 
Low: 0.1 mM; Medium: 0.4 mM; High: 0.8 mM.  *: p<0.0083 in post-hoc 
analysis for comparing the difference between the corresponding dose group 
and the untreated control group. 
Finally we compared the DC values of each drug with their IC25 values to 
H9 cells to determine whether they are teratogenic (Table 6.3.2). For 
Thalidomide, RA, D-penicillamine and VPA, the DC values were all less than 
their corresponsive IC25,H9 values, indicating that the disruption of the 
mesoendoderm pattern was likely mediated by alterations to differentiation 
and migration rather than cytotoxicity effects on the embryonic cells. 
Therefore, they were identified as teratogenic in our model. In contrast, 
Penicillin G had a much higher DC value compared with its IC25,H9 value, and 
was classified as non-teratogenic. Therefore, our quantitative morphometric 
assay based on the µP-hPSC model could correctly classify the five test 
compounds in accordance to their teratogenicity potential in vivo and showed 
a better performance when compared with the mEST.  
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Table 6.3.2 Teratogenicity screening results in the μP-hPSC model 







Thalidomide 30 μM >1000 μM Yes Teratogenic N.A.  
RA 0.36 ng/ml > 2000 ng/ml Yes Teratogenic Teratogenic  
D-
penicillamine 
200 μg/ml 278 μg/ml Yes Teratogenic Non-
teratogenic 
VPA 0.1 mM 0.13 mM Yes Teratogenic Teratogenic 




6.3.4 Concentration-dependent teratogenicity of compounds 
An important consideration when assessing for teratogenic potential is the 
dose-dependent response [1]. The effect of a potentially teratogenic compound 
may not be manifested in vivo due to a low therapeutic dose being used [128, 
145]. Therefore, an ideal in vitro screening model should not only identify 
whether a drug is potentially teratogenic, it should also be able to detect its 
teratogenic effects at clinically-relevant concentrations. The drug testing 
results in this study demonstrated the potential of the μP-hPSC model to detect 
teratogenic effects of compounds at clinically-relevant concentrations. In fact, 
when compared with the compound’s highest in vivo concentration (Cmax) in 
human plasma following therapeutic dosing, the DC values we detected for 
RA, D-penicillamine and VPA were already lower than or equal to their 
known Cmax values, indicating their strong clinical teratogenic effects (Table 
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6.3.3). In contrast, the DC value for Penicillin G was much higher than the 
highest clinical Cmax value reported in literature, which was 400 μg/ml [146], 
confirming that it was non-teratogenic (Table 6.3.3).  
Table 6.3.3 The DC and Cmax values of test compounds 
No. Compounds DC in μP-hPSC model Cmax Reference 
1 Thalidomide 30 μM 10.922 μM Teo et al. (2004) 
[147] 
2 RA 0.36 ng/ml 347 ng/ml Muindi et al. (1992) 
[148] 
3 D-penicillamine 200 μg/ml 200 μg/ml Netter et al. (1987) 
[149] 
4 VPA 0.1 mM 0.574 mM Reed et al. (2006) 
[150] 




Human-specific drug screening platforms for teratogenicity are needed to 
avoid inter-species variation problems [93]. However, current in vitro human 
PSC-based models only recapitulate temporal differentiation events [13, 14, 
16, 99, 128, 134], and overlooked other key processes during embryonic 
development, including spatial organization of differentiation and 
morphogenic movements. Our μP-hPSC model is the first in vitro human 
developmental toxicity screening model, which recapitulated both spatially 
controlled differentiation and collective cell migration processes during 
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embryogenesis. Here, we demonstrated that this model was sensitive enough 
to distinguish compound’s teratogenic potential, and exhibited better 
selectivity to human-specific effects than the mEST. 
However, we must admit that so far the advantage of our μP-hPSC model 
has only been shown when compared with the mEST and other animal-based 
assays due to a small number of compounds tested. It avoids inter-species 
variation and can correctly classify D-penicillamine which was misclassified 
in mEST due to model limitations. Compared with other existing hPSC-based 
models such as the metabolite biomarker-based hPSC teratogenicity assay and 
the hPST model, our model has shown equal performance for all of the five 
drugs tested. In order to further validate the predicitivity of our model and 
statistically compare it with current hPSC models, more drugs need to be 
tested and the classification rules may also need to be further optimized to get 
better predicitivity performance. 
7. Conclusions and Recommendations 
This dissertation has documented the establishment of a new in vitro 
hPSC-based model, which could capture both spatial differentiation and 
collective cell migration in development, for developmental toxicity testing 
application.  
Firstly, we spatially induced mesoendoderm differentiation to the 
periphery of a circular μP-hPSC colony, which possessed higher intergrin-
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mediated adhesions compared with the interior. By studying the underlying 
mechanism, we found that instead of a direct promotion of differentiation, this 
spatial correlation of mesoendoderm differentiation was likely induced by the 
corresponding destabilization of the E-cadherin AJs in regions of higher 
integrin-mediated adhesion. The destabilization of the E-cadherin AJs was due 
to the position change of the activated myosion II from the E-cadherin AJs to 
the actomyosin contractile cable caused by increased integrin adhesion-
mediated contractile stresses at the colony periphery. E-cadherin signaling was 
the primary gatekeeper of pluripotency-differentiation decision in hPSCs. 
Inhibition of Rho-ROCK-myosin II with pharmacological inhibitors (e.g. 
blebbistatin or Y27632) led to the robust differentiation of the entire μP-PSC 
colony instead of attenuated differentiation of MSCs even in an inductive 
soluble environment.  
Secondly, we formed an annular mesoendoderm pattern in our μP-hPSC 
model by geometrically confined cell differentiation and migration. When 
culturing μP-hPSC colonies for 3 days instead of 1 day in mesoendoderm 
induction medium, the differentiated mesoendoderm cells at the colony 
periphery would undergo collective cell migration process towards colony 
centre and form a 3D in vivo-like mesoendoderm pattern on d3. The migration 
speed was matrix concentration-dependent. Higher Matrigel
TM
 concentration 
led to slower migration within the μP-hPSC colonies. Different hPSC lines 
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could generate similar mesoendoderm patterns without protocol optimization, 
showing the robustness of our μP-hPSC model. 
Finally, we further applied our μP-hPSC model for human teratogen 
detection. In presence of known teratogens, the formation of the annular 
mesoendoderm pattern was disrupted in a dose-dependent manner. 
Quantitative analysis of the mesoendoderm morphologic features across 
different compound treatment groups using feature clustering and one-way 
analysis of variance (ANOVA) successfully distinguished known teratogens 
from the non-teratogens and avoid inter-species variation when compared with 
the traditional mouse embryonic stem cell test (mEST).  
The μP-hPSC platform developed in this dissertation may serve as a great 
system to systematically study the signalling mechanisms of how mechano-
sensory cues can modulate self-renewal and/or differentiation program of 
hPSCs. Here our results showed that E-cadherin was the main gatekeeper in 
hPSCs, and integrin signalling actually affected hPSC fate through 
destabilization of E-cadherin AJs (Chapter 4). In future studies, it would be 
interesting to investigate exactly how integrin-mediated tension signalling 
specifically activates the differentiation program through E-cadherin AJs. For 
example, it would be important to look at downstream integrin signaling, such 
as FAK activity, in μP-hPSCs treated with E-cadherin function blocking 
antibodies in order to correlate a gain of integrin signalling with loss of E-
cadherin at the junctions. On the other hand, we could also try to uncouple the 
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adhesion functions and the signalling functions of E-cadherin, to provide a 
better understanding of its effect on hPSC differentiation. We can overexpress 
either the extra-cellular domain of E-cadherin which is competent for adhesion 
but deficient in signalling or just the intra-cellular domain that is signalling 
competent but adhesion deficient, and test whether the T expression pattern 
within the μP-hPSC colony is maintained.  
The processes of spatial differentiation and coordinated collective cell 
migration of mesoendoderm cells in our µP-hPSC model are quite similar to in 
vivo embryo development. During gastrulation in mouse, Drosophila, or avian 
embryos, mesoendoderm cells all flow into the midline of the embryo to form 
the primitive streak and then migrate away from the streak to their desired 
location. However, the underlying mechanism of this directed migration 
process is still not fully understood so far [137, 151].  Possible mechanisms 
might involve morphological asymmetries, asymmetric signalling activities 
[137], actomyosin activity related intrinsic forces as well as extrinsic forces to 
the tissues [152]. In this dissertation, we showed that there were indeed 
asymemetries in cell-matrix, cell-cell interactions and actomyosin contractility 
within the µP-hPSC colony between the colony edge and interior (Chapter 4). 
And RT-PCR results also proved that the cells at the periphery did undergo 
EMT process and became migratory (Chapter 5). However, the exact 
mechanism of this collective cell migration process was not studied in our 
model. We only focused on mimicking and observing the collective cell 
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migration process and applied it for our drug testing application. It should be 
acceptable at this stage since the main purpose of this dissertation is to 
establish and apply this model for developmental toxicity testing. To fully 
understand the underlying mechanism of its migration process requires a lot of 
resources and effort, which can be conducted as a further extension of this 
study.  
In terms of developmental toxicity testing application, further study could 
be conducted to scientifically validate the μP-hPSC model with more test 
compounds. In order to systematically compare the teratogen screening 
performance with other existing models, at least 20-30 compounds of known 
teratogenicity should be tested altogether. A test group with enough 
compounds is required to optimize the classification rules, and an application 
group is required to evaluate the actual prediction performance of the model. 
To facilitate this systematic validation process, a scale-up of the current μP-
hPSC model may also be required. Luckily, the scalability and robustness of  
our μP-hPSC model should make it easy to implement. Our μP-hPSC model 
could also be easily combined with other data collection and analysis 
techniques applied in other hPSC models shown in Chapter 2 to study the 
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9.1 Cells in μP-hPSC colonies maintained pluripotency in mTeSRTM1 
maintenance medium 
Cells in μP-hPSC colonies could maintain pluripotency and show similar 
gene and protein expression levels compared to conventionally cultured 
hPSCs cultured in mTeSR
TM
1 maintenance medium. Immunofluorescence 
staining showed that cells were positive for the pluripotency-associated 
transcription factors OCT4 and NANOG, and surface markers TRA-1-60 and 
SSEA-4 (Fig. 9.1.1). Compared with unpatterned hPSCs in conventional 
maintenance culture, the μP-hPSCs showed similar transcript levels of both 
pluripotency-associated and lineage-specific genes (Fig. 9.1.2). 
 
Figure 9.1.1 Immunofluorescence analysis of pluripotency markers in μP-
hPSC colonies 24 hr after patterning. Expression of transcription factors 
OCT4 and NANOG and surface antigens TRA-1-60 and SSEA4 was observed. 




Figure 9.1.2 RT-PCR analysis of expression levels of pluripotency markers 
and lineage-specific markers in conventional unpatterned hPSCs and μP-
hPSCs. Unpatterned hPSCs were lysed from normal hPSC culture when cells 
were 70%-80% confluent. The μP-hPSC colonies were cultured in mTeSRTM1 
maintenance medium and lysed for RT-PCR analysis 24 hr and 96 hr post 
patterning. Both unpatterned hPSCs and μP-hPSCs showed high expression 
levels of pluripotency markers and low expression levels of lineage-specific 
markers. Pluripotency markers: NANOG, OCT4, SOX2; Mesoendoderm 
markers: T, MIXL1, GSC, NKX2.5, FOXA2 and SOX17: Ectoderm markers: 
PAX6, NES (nestin). Data are average ± s.d of three experiments with 
duplicate samples. *, p<0.05 in paired t-test.  
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9.2 Culture of hPSCs on E-cadherin Fc-coated tissue culture polystyrene 
substrates 
E-cadherin-Fc (EcadFc) could be used to culture hPSCs. hPSCs could 
attach to EcadFc-coated tissue culture polystyrene substrates in a dose-
dependent manner (Fig. 9.2.1).  Cells could attach, spread and proliferate well 
when the coating concentration of EcadFc was 10 μg/ml and 40 μg/ml without 
significant morphological differences between these two concentrations, while 
2 μg/ml EcadFc coating concentration was too low for proper cell attachment 
and spreading (Fig. 9.2.1).  
 
Figure 9.2.1 Attachment of hPSCs on different concentrations of E-cadherin 
Fc-coated tissue culture polystyrene. Single hPSCs were seeded and cultured 
in defined maintenance medium (mTeSR1, Stem Cell Technologies). Images 
were taken at (a) 6 hr and (b) 48 hr post seeding. Scale bars = 100 μm. 
EcadFc could also maintain hPSC pluripotency when cells were cultured 
in defined maintenance medium (mTeSR1, Stem Cell Technologies) (Fig. 
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9.1.2). The expression levels of pluripotency markers Oct4 and Nanog were 
comparable with hPSCs cultured on Matrigel-coated substrate. 
 
Figure 9.2.2 Pluripotency markers expression in hPSCs on Matrigel
TM
 or 
EcadFc (10 μg/ml)-coated substrates 48 hr post seeding. Data are average ± 
s.e.m of 3 experiments. 
9.3 Integrin and E-cadherin antibody blocking 
In order to find the major integrins involved in hPSC attachment to 
Matrigel substrate, inhibition of cell-matrix adhersion by integrin antibodies 
was performed. Three integrin antibodies,  α5β1,  α2β1 and α6β1 antibodies were 
added into the hPSC single cell suspension while cell seeding. After 4 hr 
incubation for cell attachment, untreated cells and cells treated with α5β1 and 
α2β1 antibodies spread more onto the substrate compared with cells treated 
with α6β1 antibodies, indicating decreased cell-matrix adhesion in α6β1 
antibody-treated samples (Fig. 9.3.1). When mesoendoderm differentiation 
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was induced to these α6β1 antibody-treated samples, a dose-dependent 
contraction of μP-hPSC colonies could be observed (Fig. 9.3.2). After 24 hr 
differentiation induction, the sizes of colonies treated with 0.1 μg/ml α6β1 
antibodies were about 50% of the untreated ones (Fig.9.3.2). In contrast, sizes 
of colonies treated with α5β1 or α2β1 antibodies showed no significant 
differences compared with untreated control samples (Fig. 9.3.3). Therefore, 
we can conclude that the main integrin involved in cell attachment onto 
Matrigel is α6β1, instead of α5β1 and  α2β1. By adding α6β1 antibodies into the 
culture, integrin-dependent cell-matrix adhesion of hPSCs on Matrigel-coated 
plates could be disrupted. 
 
Figure 9.3.1 hPSC attachment to micropatterned Matrigel substrate in the 
presence of integrin antibodies after 4 hr incubation post cell seeding. (a) 
Untreated control, (b) 1 μg/ml α5β1, (c) 1 μg/ml α2β1, (d) 0.1 μg/ml α6β1 




Figure 9.3.2 Blocking of laminin- α6β1 integrin binding by α6β1 antibody 
caused contraction of differentiating μP-hPSC colonies in a dose-dependent 
manner. (a) Phase images showing μP-hPSC colonies at the onset (0 hr) and 
after (24 hr) mesoendoderm differentiation. There was no significant 
differences in the colony sizes at different antibody concentrations before 
differentiation was initiated. α6β1 antibody-treated colonies contracted after 24 
hr of differentiation. Scale bars = 400 μm. (b) Quantification of colony areas 
at different concentrations of α6β1 antibody. Data are average ± s.e.m of 
different sample sizes (n): Control (n=8); 0.1 μg/ml (n=6); 0.5 μg/ml (n=2); 




Figure 9.3.3 Specific inhibition of integrin α6β1-laminin binding attenuated 
cell-ECM interaction and resulted in contraction of μP-hPSC colonies. (a) 
Phase images of μP-hPSC colonies after 24 hr of mesoendoderm 
differentiation in the absence (control) or presence of 1 μg/ml α5β1, 1 μg/ml 
α2β1 and 0.1 μg/ml α6β1 integrin antibodies. Scale bars = 200 μm. (b) 
Quantification of colony areas after 24 hr of differentiation. Data are average 
± s.e.m of different sample sizes (n): Control (n=8); α5β1 Ab (n=5); α2β1 Ab 
(n=7); α6β1 Ab (n=6). * indicates statistical significance when compared to 
control colonies (Student’s t-test, p<0.01). 
When adding E-cadherin antibodies into the hPSC culture since cell 
seeding, cell-cell interactions within the colonies could be disrupted. After 24 
hr of differentiation, more scattered morphology of cells could be observed in 





Figure 9.3.4 Specific inhibition of E-cadherin-mediated adhesion in the μP-
hPSC colonies resulted in more scattered morphology. (a,b) Phase images of 
colonies treated with E-cadherin antibody and differentiated for 24 hr. (c,d) 
Phase images of control colonies treated with unspecific IgG antibody and 
differentiated for 24 hr. Scale bars in (a,c) = 200 μm, (b, d) = 100 μm. 
 
 
